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Abstract	
In 2017, it was reported that a number of 962 million people were 60 years old or older 
globally. In other words, nowadays we are already facing an aging society. The increase aging 
population will bring an increase number for those age-related body disorders which result 
from lifelong molecular and cellular impairments. Common age-related body disorders are 
cardiovascular disease, cancer, diabetes mellitus and chronic respiratory disease. In addition, 
aging people are easier to suffer multimorbidity, for example, 10% cardiovascular disease is 
reported to be caused by diabetes mellitus. Multimorbidity brings more difficulties to treat the 
aging people more properly and effectively. Besides, clinicians have realized that the response 
of different patients to the same medical treatment can differ. Above all, individual 
characterisation of one’s unique condition is in higher demanded than ever before. 
Personalized medicine, an emerging and rapidly developing field beneficial from human 
Genome project, is potential to offer a molecular or genomic diagnosis and to realise early 
disease detection, targeted disease prevention, accelerated diagnosis, and targeted therapies. 
Personalized medicine crucially depends on the identification of biomarkers and the 
development of accurate and reliable diagnostics. Those advanced diagnostic approaches to 
provide rapid and accurate information on genetic or molecular scale are in particularly high 
demanded. Pathological variations are always accompanied by biochemical changes from 
cells, body fluids, or tissues. Vibrational spectroscopy, including Raman spectroscopy and 
Fourier transform infrared spectroscopy, is one of the favourite techniques being developed 
for personalized medicine. It owes advantages of non-destructive, rapid, label-free, high-
throughput and biochemical fingerprint on molecular level. Therefore, these techniques can 
ideally capture the biochemical changes, especially when they are applied together. Among 
the samples measured by vibrational spectroscopy, body fluids are very popular due to its 
easy accessibility with minimal invasiveness. In particular, blood and its components are the 
most frequently studied samples for disease diagnostics since they can be easily obtained 
repeatedly. However, blood is such a complex body fluid that improper sample preparation 
can degrade its quality for clinical purpose. Thus, it is rather challenging to find a proper and 
reproducible sample preparation approach when employing vibrational spectroscopy to study 
blood specimen. Drop coating deposition method is one candidate to prepare blood-based 
samples with high quality and minimal amount. However, the redistribution of plasma 
proteins in the prepared droplet samples and superior measurement schematics to collect 
vibrational spectra for biomedical application remains as open issues. Moreover, to pave the 
way of vibrational spectroscopy into daily medical application, the robustness of vibrational 
spectroscopic analysis using minimal amounts of blood to stratify patients from different 
disorder cohorts still needs to be proved.  
In this thesis, the aforementioned challenging issues are addressed and detailed solutions are 
presented, including (1) quality check and drop coating deposition method by using blood 
sample for spectroscopic analysis; (2) application of vibrational spectroscopy to diagnose and 
follow-up treatment of cardiac diseases; (3) applying Raman spectroscopy to characterize 
glycated haemoglobin in diabetes mellitus for diagnostics. These investigated issues involve 
different specific topics: (1) time delays between blood collection and centrifugation are often 
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unavoidable. During the different time delays, blood can undergo different changes which 
influence its quality and limit its clinical application. Hence, a quality check of blood 
specimen to investigate the spectral changes of studied samples is conducted. This study 
should give hints which time delays are still acceptable for reliable and reproducible 
subsequent spectroscopic analysis. (2) By drop coating deposition the plasma or serum 
sample onto Raman- or IR-free substrate, the biomolecules will be pre-concentrated at 
different regions due to coffee-ring effect. Understanding of plasma protein distribution in the 
droplet remains unclear, and study on superior measurement schematics for vibrational 
spectra in biomedical applications is in demanded. After figure out the issues on quality check 
of blood sample and the appropriate spectroscopic measurement protocol, clinical 
applications will be discussed in the following sections. (3) Mechanisms of various cardiac 
diseases are in variety, resulting in different approaches to detect the cardiac conditions and in 
need of versatile treatment strategies. There is room and need to investigate the differentiation 
of different cardiac diseases, and to study the differences between cardiac condition and 
healthy condition. After characterization of different cardiac disorders, two studies of 
different treatments corresponding to different cardiac disorder will be introduced and 
discussed subsequently, including immunoadsorption therapy and coronary artery bypass 
surgery. (4) Immunoadsorption therapy is a therapy to treat the patients who are suffering 
from dilated cardiomyopathy. This therapy improves left ventricular ejection fraction by 
substituting the original anti-cardiac antibodies with pooled immunoglobulin G. Vibrational 
spectroscopy is used to interpret longitudinal changes according to immunoadsorption 
therapy. (5) Coronary artery bypass surgery is one of the preferred procedures to restore 
normal blood flow to an obstructed coronary artery. This surgery can cause an inflammatory 
response in the patient, especially when perform with heart-lung-machine. In this context, 
vibrational spectra from plasma samples before and after the surgery are investigated. (6) 
Finally, the biomedical focus will move to the characterization of glycated haemoglobin using 
Raman spectroscopy. Glycated haemoglobin, a non-enzymatic glycosylation of haemoglobin 
product, reflects an average blood glucose level for last 120 days and becomes one of the 
common diagnostic methods for diabetes mellitus. Raman spectroscopy is applied to 
characterize glycated haemoglobin, particularly to investigate glycated haemoglobin value on 
single red blood cell level. 
Key words: vibrational spectroscopy, blood, personalized medicine, biomedical application, 
cardiac disease, diabetes mellitus, chemometrics 
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1 Introduction	
1.1 Medical	need		
Nowadays, we are already facing the aging society. According to the World Report on Aging 
and Health released by World Health Organization in 2015, the number of people aged 60 or 
older will rise from 12% in 2015 to 22% in 2050 globally. [1] Aging accompanies with 
different impairments in many body functions which are caused by molecular and cellular 
damage along lifelong time. Thus, the aging people hold high potential to risk disease and 
death, especially to experience age-related chronic diseases. In another report from World 
Health Organization “World health statistics 2016: monitoring health for the sustainable 
development goals” [2], about 68% mortality was resulted from non-communicable death, 
with the number of 38 million deaths per year in 2012. Over three quarters of this global 
premature mortality is contributed from cardiovascular disease (CVD), cancer, diabetes 
mellitus (DM) and chronic respiratory disease. Premature mortality refers to death at the age 
under 70 years old. CVD caused 17.5 million deaths in 2012 - 6 million of them were under 
age 70, while diabetes lead to 1.5 million deaths - 43% of them occurred under the age of 70. 
[3] Study has shown that between 1990 and 2013, the growth of aging and population resulted 
in a higher global cardiovascular mortality. [4] What even worse, as the people are growing 
older and older, they are easier and higher possible to suffer multi-morbidity - which means 
experiencing multiple (chronic) diseases simultaneously. For example, DM is a common risk 
factor for CVD, causing about 10% CVD. Besides the chronic unhealth condition of the aging 
society, the economic burden on those more age-related diseases are huge. The global cost of 
CVD in 2010 was 863 billion US dollars, and the cost has estimated to be 1,044 billion US 
dollars in 2030. [5] DM directly costs 827 billion US dollars annually, it has estimated to loss 
1.7 trillion US dollars in GDP worldwide from 2010 to 2030. [3] 
When the patients under the same condition are diagnosed as the same disease, they are more 
likely to be given the same treatment, but the clinicians have found that different patients can 
respond differently to the same medical intervention. The efficiency of the same treatment on 
the patients with the same condition can be only 30 - 60% [6]. For example, about 40% 
cardiac arrhythmias patients will not benefit from the cardiac arrhythmias drugs and 
approximately 43% in the case of diabetes patients. [7] This is easy to understand, our health 
is determined by many factors, like our genes, our lifestyles, and even other environmental 
factors. In other words, we are all unique. To better identify our healthy patterns, personalized 
medicine will be more superior for the symptom driven broad diagnosis. Personalized 
medicine is a field flourished from the human Genome project [8] , which is advancing 
rapidly with individual characterisation of underlying cause (a person’s unique genetic, 
genomic, environmental, and clinical information) [9]. So far, personalized medicine has 
gained higher and higher global attention for its potential benefits including early disease 
detection, targeted disease prevention, accelerated diagnosis, and targeted therapies. 
Personalized medicine helps to improve clinical outcome and decrease the side-effect of 
inappropriate treatment. Health systems in many different countries like US, Germany, 
Canada, Austria, China, France and India are now working on policies and research projects 
to support and adopt the personalized medicine into their health care system.  
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Personalized medicine is able to detect or diagnose the disease at an early stage even before 
the onset of the symptoms. The early detection has high potential to reduce the growing 
burden of disease, to improve the outcomes for patients and our population, especially for the 
abovementioned long term disorders such as CVD and DM. The success of personalized 
medicine crucially depends on the identification of biomarkers and the development of 
accurate and reliable diagnostics. [10] There is space and demand to study advanced 
diagnostic methods which can help to diagnose more precisely with genetic or molecular 
information. Among the numerous promising diagnostic and therapeutic approaches, 
biophotonics is expected to play the leading role. [10] Biophotonics investigates the 
interaction between incident light and biological sample, and is an emerging and rapidly 
developing multidisciplinary research field. By employing light technique, the structures and 
functions on cellular or molecular level can be explored rapidly and noninvasively with 
utmost sensitivity and precision. These advantages make biophotonics a unique tool to 
understand disease on molecular level, recognise disease at early stage, target treatment of 
diseases and prevent disease [10]. Among the various biophotonics techniques, vibrational 
spectroscopy including Raman spectroscopy and Fourier transform infrared (FT-IR) 
spectroscopy is one of the favourite choices due to its non-destructive, rapid, label-free, and 
biochemical features, which will be discussed in more details later.  
1.2 Motivation	
Vibrational spectroscopy has high ability and possibility to monitor the biomolecule 
compositions and variations from samples, it holds potential to diagnose pathologies rapidly 
at an early stage. However, when investigating the potential of vibrational spectroscopy for 
diseases detection using blood samples, following issues are needed to obtain further 
understanding.  
(1) Quality check of blood specimen 
Blood, referred as ‘liquid organ’, is a complex biological specimen which contains many 
types of components with very dynamic range properties. [11] Since blood distributes through 
the whole body, it exhibits a wide variety of functions and reflects the real physiological 
condition. Blood is mainly divided into two parts - blood cells and blood plasma, for more 
details please refer to Section 1.3. These two parts can be separated by centrifugation 
according to their different physical chemistry properties. Due to its accessibility and 
complexity, blood is a widely used specimen for clinical study. Since the last decades, there 
have been a lot of studies about biomarker discovery based on plasma or serum proteomics 
[12-17], also based on plasma or serum metabolomics [18-20]. Blood plasma or blood serum 
compromise of various biomolecules such as peptides, amino acids, lipids, proteases, 
enzymes, cytokines, low molecular weight metabolites, electrolytes etc. When there is 
physiological misregulation with the presence of disease, the biomolecular variation will 
transit to the circulating bloodstream, then retain in blood plasma or blood serum. Thus by 
hunting for the biomarkers in plasma or serum, it is able to detect the disease. However, there 
remain challenges in biomarker discovery based on plasma or serum: (1) inherent biological 
variability; (2) the plasma proteomics has a large dynamic range of protein concentrations, 
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covering at least 10 orders from ݉݃/݈݉  to ݌݃/݈݉ ; (3) plasma metabolomics is mainly 
interested in low-molecular weight compounds (molecular weight ൏ 	1,500	ܦܽ) [21], without 
any processing in sample preparation, the metabolomics is dominated by the abundant plasma 
proteins including albumin, immunoglobulin, etc; (4) the variability in pre-analytic and 
analytic processes, including the blood collection tubes, the time delay between blood 
collection and centrifugation, storage temperature, storage time, the frozen-thaw circles and 
so on.  
To minimize the aforementioned challenges, especially those non-intrinsic artefacts such as 
pre-analytical variables, it is necessary to follow the standard operating procedure (SOP) to 
obtain high quality and reproducible samples. However there are different SOPs 
recommended for blood specimen preparation, and the importance of pre-analytical variables 
still remain in questions. The use of improper blood collection tubes will affect the 
subsequent searching of biomarkers. The blood can be collected as anti-coagulated plasma or 
coagulated serum. For anti-coagulated plasma, different anti-coagulants mechanisms need to 
be considered to prevent blood clot. Ethylenediaminetetraacetic acid (EDTA) is an 
aminopolycarboxylic acid and chelates metal ions like Ca2+, Mg2+. EDTA blood is not a 
good choice for the measurement in which divalent cations are necessary. Citrate is in liquid 
form and will dilute the collected sample, it can bind Ca2+ in a non-dissociation form. Citrate 
blood has shown artefacts for immunoassay measurements. Heparin, a sulphated 
glycosaminoglycan which binds to antitrombin III and accelerates the inactivation of 
thrombin and other clotting factors, can interference in some affinity processes. [22-25] After 
blood collection, in order to have high quality specimen, serum need time to clot properly 
while plasma can be centrifuged immediately. However, in reality it is often and easy to have 
a time delay between blood collection and blood centrifugation. This can be due to the 
geographic distance between the clinic and the blood processing facilities, the busy of 
laboratory equipment and centrifuge. Such pre-analytical issues will influence the quality of 
blood specimen, studies about the pre-analytical issues and the quality of blood specimen can 
be found in Ref [21-23, 25-34].  
In clinic reality, many pre-analytical issues such as blood collection tubes, storage 
temperature are fixed, but the time delay between blood collection and centrifugation is very 
easy to be varied. It is common to keep the blood for up to 4 hours for further processing in 
clinical lab [31]. But during this prolong storage time, especially at room temperature, the 
intrinsic biochemical process of blood continue going, including enzymatic proteolysis and 
erythrocyte activity. The former endogenous proteolytic activity will cause proteins to 
experience degradation, while the latter alters the blood metabolome that are reflected in 
subsequent plasma and serum profiles. [25, 33, 35] 
For clinical studies, we had collaboration with the physicians; they collected the blood from 
the patients and then transferred the blood to us. After we received the blood from the doctors, 
the blood was centrifuged according to our SOP immediately once the devices were 
applicable, or the blood was delayed no more than 2 hours to be centrifuged. Issues about how 
long can the blood delay to be centrifuged, and how stable can the blood be after certain time 
delay are essential to be investigated to have high quality specimen. 
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When using specific metrology for clinical application, the study of quality and stability of 
blood specimen is critical. Since the last decades, when combining the dried droplet of plasma 
or serum with Raman spectroscopy, there have been lots of researches about biomolecular 
changes from blood plasma or serum for diagnostic purposes. The technique with the name of 
drop coating deposition Raman (DCDR) spectroscopy was first put forward by Dongmao 
Zhang. [36] This technique is able to improve the detection sensitivity more than 1000 times 
beneficial from the pre-concentration of biomolecules. Since then, this technique has been 
widely investigated, especially for the biomedical application. So far, there is no study on the 
stability of DCDR regarding the time delay between blood collection and blood 
centrifugation. Thus, the investigation of Raman spectroscopy for the quality check of blood 
specimen about the delay between blood collection and blood centrifugation is conducted. 
(2) Vibrational spectroscopic investigation of blood plasma and serum by drop coating 
deposition for clinical application 
When a drop of body fluids, e.g. blood plasma, or blood serum, is placed on a solid substrate 
and allowed for drying, an interesting phenomenon called ‘coffee-ring effect’ will show up 
with ring-shape deposited at the edge of the dried droplet. Several conditions are required to 
form the coffee-ring effect: self-pinning of liquid-substrate contact line, higher evaporation 
rate at the contact line, and suppression of Marangoni flow. [37] In short words, when a drop 
of biological liquid is placed on a solid slide, the enhance evaporation rate at the pinned 
liquid–substrate contact line will induce an outward capillary flow in liquid, this outward 
capillary flow carries the suspended molecules from the interior to the edge. [38-40] While 
the droplet is evaporating, the temperature gradient along the surface of the drying droplet 
will lead to a surface-tension gradient which will induce thermal Marangoni flow. The 
Marangoni flow carries particles on the surface of the droplet inward toward the top of the 
droplet, and then plunges the particles downward to be absorbed on the substrates near the 
centre of the droplet or to be carried along the substrates to the edge causing a circular 
movement along the drop-air interface of the droplet. [41, 42] After drying, the droplet will 
have an inhomogeneous redistribution with most molecules concentrated at the edge as the 
co-result of coffee-ring effect and suppression of thermal Marangoni effect.  
The drying process can form cracking patterns on the final dried droplet. During drying 
process, a particle film will be formed on the top layer of the droplet, and the substrate 
constraints will increase tensile stress in the drying droplet. The cracking patterns are caused 
by the mismatch between the horizontal shrinkage of the particle film and the substrate 
constraints. When the increased tensile stress exceeds the tensile strength at some locations of 
the film, cracks will occur to release the stress. Since most suspended particles in blood 
plasma and serum are soft, they can delay the occurrence of cracking by absorb more stress 
and reduce the evaporation rate. [37] 
After deposition of plasma or serum on a wettable solid slide, most protein molecules will be 
driven toward the contact line and concentrated at the edge, while the high soluble inorganic 
electrolytes and maybe some proteins will be located towards the centre of the droplet. In the 
centre of the droplet, crystal patterns will be formed. 
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It has been a long time to investigate biomolecular changes caused by disease in dried droplet 
of plasma or serum. These changes are able to be utilized for diagnostic purposes, especially 
when combining the droplets with vibrational spectroscopic techniques like Raman 
spectroscopy and FT-IR spectroscopy which extract biochemical information of samples in a 
non-invasive and rapid way. By drop coating deposition method, the interference of solvents 
can be reduced or avoided to certain extent. Besides, the volume of sample preparation needs 
only few nanoliter, and the proteins in the sample will be pre-concentrated and segregated. 
These are especially advantageous for body fluids samples. 
Even though there are many studies on the investigation of disease by the combination of 
vibrational spectroscopy and drop coating deposition method, many challenges are remained 
to be solved. One challenge is to reduce the droplet size, this can be achieved by robotic 
method via standard laboratory technique. Another challenge is to choose appropriate 
measurement positions better representing the whole droplet instead of measuring the big 
whole droplet which will be very time-consuming.  
So far, many studies on the drop coating deposition combined with vibrational spectroscopy 
are for the disease diagnosis, or directly biomedical application. But there are request to 
understand the distribution of plasma proteins in the dried droplet, the superior measurement 
schematics for biomedical application. In this thesis, I study the locations of the most 
abundant albumin and immunoglobulin G (IgG) in the plasma and serum droplet, the 
difference between inner and outer region in the plasma or serum droplet, and the superior 
measurement schematics for biomedical application. To our knowledge, this is the first study 
to investigate the abovementioned issues. 
(3) Vibrational spectroscopic differentiation of patients suffering from various cardiac 
diseases 
Nowadays, we are already facing the aging society. The aging population will accompany a 
lot of health problems, especially of chronic diseases which result from molecular and cellular 
damage through lifelong time. In those disease conditions, CVD is the number one cause of 
mortality. Even worse, the death caused by CVD will rise with respect to aging, this is 
supported by the study of Roth and his colleagues [4]. In their study, they tried to find out the 
relationship between the three principal drivers (population growth, population aging, and 
epidemiologic changes) and global cardiovascular mortality by using the data from 1990 to 
2013. Their results suggested that even though there was an overall decrease in age-specific 
mortality in most regions between 1990 and 2013, the population aging and population 
growth resulted in an increase in global CVD mortality. Aging attributed about 55% increase 
for this increase from 1990 while population growth contributed for 25.1% increase. Due to 
the high mortality of CVD, it has attracted our attentions to reduce the corresponding death. 
For example, United Nations has set a goal to reduce 25% premature mortality due to CVD 
by 2025. [43, 44]  
CVD has been recognized and investigated for a long time, and the disciplinary called 
cardiovascular science or cardiology has been formed. Modern cardiology is considered to 
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begin based on the discovery of blood circulation by William Harvey in the early 17th 
century. Thereafter, the descriptive anatomy and pathology, auscultation, pathophysiology for 
CVD have been pursued for centuries. Since the advent of cardiac catheterization and surgery 
in 1950s, cardiology has become more complex and has been expanded into multiple higher 
specialized subdisciplines including coronary artery disease (CAD), arrhythmias, HF and 
preventive care [45]. For 21st century, incredible tools for diagnosis and treatment of heart 
disease have been advanced. [45] These advanced diagnosis tools mainly benefit from the 
understanding of blood biomarkers; multiple imaging modalities with higher sensitivity and 
higher spatial and temporal resolution. The treatments have been improved with further 
investigation of pharmacogenomics profiling, biological molecules, bionic heart, genomic 
discoveries and stem-cell therapy [45-49]. Thanks to the scientific advances on cardiovascular 
medicine including early diagnosis of cardiac risk, improved medical treatment for cardiac 
diseases, and also the increasing consensus of prevention, a large number of CVD has been 
prevented successfully thus reducing the mortality of CVD [4, 46, 50-52].  
The term CVD is quite large. It is a class of diseases not only from the heart, but also contain 
vascular disease of the brain and the diseases from blood vessels [50]. CVD involves not only 
various underlying mechanisms and complex genetic factors for pathogenies, but also certain 
risk-factors. The variety makes some persons more prone to develop certain CVD conditions, 
while some will not benefit from the same treatment given to those with similar clinical 
presentations. It has been reported that only 30-60% efficiency of the same treatment works 
for the patients with the same condition. [6] 
For the variety of CVD, some disorders (myocarditis, dilated cardiomyopathy (DCM), 
Takotsubo cardiomyopathy (TTC), and heart failure (HF)) are explained here as medical 
background for our patient cohorts.  
Myocarditis, also known as inflammatory cardiomyopathy, is characterized as inflammatory 
cellular infiltrate associated with cardiac dysfunction. [53-55] Even though it is still unclear 
about the true incidence of myocarditis [54], acute myocarditis has been reported to have a 
slight prone in male than in female [56-58], which can be resulted from the protective effect 
of natural hormone changes on the immune responses in female [59]. Myocarditis has 
versatile symptoms, ranging from mild dyspnea or chest pain to cardiogenic shock and death. 
Also the pathogens for myocarditis are various, including viral infections in most cases, toxic 
or hypersensitivity drug reactions, giant-cell myocarditis, and sarcoidosis. According to the 
studies of virus-induced autoimmune myocarditis based on rodent models and isolated cell 
systems, detailed knowledge has been discovered. [54, 55] Viruses enter cardiac myocytes or 
macrophages through specific receptors and coreceptors, and then the innate immune system 
will be activated for host defence. Over weeks, adaptive immunity which is mediated by T 
lymphocytes and antibodies will be triggered directly against the viral pathogens. The 
endogenous heart epitopes will cause robust inflammation. In the early stage of viral 
infection, it can be accompanied by immunoglobulin M antiviral antibodies, these antibodies 
can change to persistent antiviral IgG antibodies in the subsequent sub-acute and chronic 
phases. [55] Most patients undergo viral elimination and down-regulation of the immune 
reaction with few permanently detrimental to the heart; while other patients can not clear the 
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virus pathogens thus cause persistent myocyte damage with long-term sequelaes such as 
DCM with chronic heart failure symdroms. Myocarditis can be diagnosed via endomyocardial 
biopsy invasively, and via cardiac magnetic resonance noninvasively. Besides, 
electrocardiogram and the increased value of cardiac troponin I can also be used as diagnostic 
choices. Myocarditis can adopt conventional HF therapies and sudden cardiac death 
prevention to improve left ventricular dysfunction. Moreover, with the advances on immune-
related research, different immunomodulatory treatment can be considered as treatment 
approaches. These immunomodulatory approaches include immunosuppression, intravenous 
Ig treatment, antiviral immunomodulation with interferon, last but not least 
immunoadsorption (IA).  
DCM, one sequelae of myocarditis as aforementioned [54, 55], is the most common 
cardiomyopathy. DCM is characterized by dilation and contraction dysfunction of the left or 
both ventricles with normal left vertricular wall thickness, but without the occurrence of 
abnormal loading conditions and severe coronary artery disease [60-63]. This disorder can 
develop at any age without preference of gender and ethnic origin [60]. But it occurs more 
commonly in male adult than in female adult [60]. DCM is one of the most frequent causes of 
HF and the most common cause for heart transplantation, [55, 60-62, 64] which has high 
possibility for hospital admission and will result in large cost burden. It often fails to figure 
out the specific etiology for DCM, since DCM is common to be diagnosed at the end-stage. 
The pathologies for DCM are with a variety of primary and secondary causes. These causes 
include infectious agents, bacterial, fungal rickettsial, mycobacterial, parasitic, toxins, 
excessive alcohol, autoimmune and systemic disorders etc. Among them, postviral 
autoimmunity is expected to play a vital role [65] with the production of anti-cardiac 
antibodies resulting from activation of the humoral immune system. Regarding DCM, so far a 
number of autoantibodies which against cardiac structures have been identified [55, 66-68]. 
Imaging strategies such as echocardiography, electrocardiography and coronary angiography 
are applied to diagnose DCM, other diagnostic methods include viral serology and 
endomyocardial biopsy. Similar to myocarditis, DCM can be alleviated by the conventional 
HF treatments in medical or surgical way, also by immunomodulatory therapies.  
Unlike the most common cardiomyopathy - DCM, TTC is quite new and was initially 
reported by Sato in Japan in 1990. [69, 70] TTC is characterized by transient systolic and 
diastolic left ventricular dysfunction, involving left ventricular apex and/or mid-ventricle in 
the absence of blocked coronary artery disease. [62, 63, 70] TTC has an unusual shape for the 
left ventricle with a narrow upper portion but a lower enlarged portion, this shape resembles 
the Japanese ceramic trap for octopus, this is where the name from. [69, 70] This disorder, 
also named as stress cardiomyopathy, is most likely (85%) to be triggered by emotional or 
physical stress [69], maybe with a prevalence of physical triggers over the emotional triggers 
[71]. TTC includes predominant clinical symptoms such as chest pain, dyspnea and syncope, 
but also with less common pulmonary edema [69, 70] and mild enzyme elevation [63]. Most 
takotsubo events are reversible, and can be recovered rapidly within days or weeks. The 
mechanisms for this disorder remain unclear, but are suggested to be caused by multivessel 
epicardial coronary artery spasm, microcirculation dysfunction, obstruction of the left 
ventricular outflow tract, catecholamine cardiotoxicity and metabolic disturbance. [72, 73] 
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Besides, TTC has been reported with a prevalence in female, especially for post-menopausal 
women [72, 73], suggesting the facilitating role of estrogen deprivation mediated by 
endothelial dysfunction. So far, there are not worldwide diagnostic criteria for TTC, several 
diagnostic criteria have been proposed where Mayo Clinic criteria is the most commonly used 
one. [70] Briefly, treatments of myocardial ischemia should be managed based on the initial 
acute MI- like presentation. After confirmation of TTC, subsequent treatments will be 
determined by the complications during the acute phase. The subsequent treatments include 
intravenous fluids and inotropic agents for shock, and standard HF therapies with diuretics or 
nitroglycerin. [69, 70]  
Heart failure (HF) is a syndrome rather than disease in which the heart cannot supply enough 
blood to the body. HF can result from structural or functional cardiac abnormalities with 
various symptoms (e.g. fatigue, breathlessness) and signs (e.g. pulmonary crackles, peripheral 
oedema). [48, 74, 75] HF is usually classified into two classes based on the contract ability of 
the left ventricle - HF with reduced left ventricular ejection fraction (LVEF) (≤40%) or HF 
with preserved ventricular ejection fraction (≥50%). Another important distinction between 
chronic and acute HF is that acute HF requires urgent diagnosis and management and 
followed by unscheduled hospital admission [75]. Several pathogenic mechanisms have been 
discovered for HF: hemodynamic overload for reduction in intrinsic contractility of cardiac 
muscle, ventricular remodeling, inadequate or excessive proliferation of the extracellular 
matrix, ischemia-related dysfunction, overload neurohumoral stimulation, unusual myocyte 
calcium cycling, accelerated apoptosis and genetic mutations. [48, 74] With the help of 
biomarkers, it is easier to identify the pathogenesis of HF, estimate prognosis and choose 
proper therapy, especially when utilizing multiple biomarkers simultaneously. These HF 
biomarkers include myocyte stretch markers such as brain natriuretic peptide and soluble ST2 
cardiac biomarker, myocyte injury markers such as cardiac troponin I and cardiac troponin T, 
extracellular matrix remodeling markers such as collagen propeptides, inflammation markers 
such as C-reactive protein (CRP) and interleukin 6 (IL6), oxidative stress markers such as 
oxidized low-density lipoproteins, neurohormones marker such as angiotensin II and 
norepinephrine, and new markers such as galectin 3 and adiponectin. [76, 77] Treatment of 
acute HF has gentle changes with the focus on haemodynamics in the past decade, where 
chronic condition has been the prime target in new research. These therapies include but not 
limit to positive inotropic agents, pharmacologic treatment, stem cell therapy, cardiac 
remodeling and recovery, and gene therapy. 
CVD has a broad range, the pathogenesis and therapy managements are various. More efforts 
are needed to reveal the unclear mechanisms and to propose more advanced and effective 
therapies. Vibrational spectroscopy, as a robust technique for clinical study, holds the 
potential to uncover the remaining mystery of CVD. 
(4) Immunoadsorption therapy follow‐up for dilated cardiomyopathy using vibrational 
spectroscopic methods 
As abovementioned, DCM is the most common cardiomyopathy, which is defined by left 
chamber enlargement and left ventricular dysfunction without the presence of abnormal 
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loading conditions like coronary artery disease [62, 63, 78]. DCM has prevalence in male than 
in female, and is the number one cause for heart transplantation. [55, 64] As DCM progressed, 
it is often diagnosed at the end-stage without the ability to find out the specific pathology. [78] 
The etiology of DCM is of a variety and has not been fully understood, a lot of studies are still 
undergoing investigation to find out the underlying physiopathology. DCM is considered as 
‘mixed’ cardiomyopathy, including genetic and acquired causes. [62] A familial form of up to 
30% is recognized in DCM patients, suggesting a genetic basic cause for this cardiac disorder. 
The acquired causes for DCM phenotype are various, including the followings: infectious 
agents, such as viruses, bacteria, fungi, parasite; toxins, e.g. alcohol; as well as autoimmune 
and systemic disorders. [55, 62, 63, 78, 79] Among the various acquired causes, post-viral 
autoimmunity is suggested to play a critical role. [65] Furthermore, anti-cardiac antibodies are 
also supposed to play an important role in DCM by activating the humoral immune system. 
According to literatures, a number of autoantibodies against different cardiac structures have 
been identified [55, 66-68]; these autoantibodies include Ig against G-protein-linked receptors, 
troponin I, cardiac ß-1 receptors and cardiac myosin. Studies have shown that anti-cardiac 
antibodies belong to IgG 3 subclass and can be eliminated by IA therapy. [66-68, 80-82] 
However, the functional significance of these anti-cardiac autoantibodies is not clear yet and 
is still under debate. Symptoms related to chronic HF, i.e. dyspnea, angina, pulmonary 
congestion, fatigue, systolic and diastolic dysfunction and peripheral oedema may be 
observed in DCM patients. Additionally, DCM patients may also accompany with the 
complications including arrhythmias, sudden cardiac death and thromboembolic events. 
Before diagnosis, the history of DCM patients should be acquired, including risk factors for 
CAD. [9]  
DCM can be characterized via different medical imaging approaches, including (two-
dimensional) echocardiography, electrocardiography, and coronary angiography. Besides, 
viral serology and endomyocardial biopsy are also often applied to diagnose DCM. Since 
DCM shares the symptoms of HF, HF managements are adopted to treat DCM disorder. The 
HF treatments involve medical methods such as angiotensin-converting-enzyme inhibitor and 
ß-blocks to decrease the risk for sudden cardiac death, and surgical approaches by inserting 
continuous-flow pumps, assist devices or undergoing heart transplantation as the last choice. 
[55, 68] Apart from the HF treatments mentioned above, immunomodulatory therapies have 
been studied. IA therapy removes the anti-cardiac autoantibodies by removing IgG, and has 
shown potential to improve the heart function of DCM patients, even alleviate myocardial 
inflammation in some cases of DCM-induced HF. In general, IA depletes anti-cardiac 
antibodies from the patients’ plasma, without [83] or with [66, 67, 80, 81] the substitution of 
IgG after the removal. In consideration of infection, IgG will be substituted after IA to restore 
the IgG plasma levels. IA therapy is usually under 1 course at 5 consecutive days. [81] After 
this 5-day treatment, fresh IgG will be substituted. [82] IA holds the potential to improve the 
function of LVEF and decrease cardiac biomarkers of HF and cardiac congestion such as 
natriuretic peptides [76, 80]. The improvements of IA on HF symptoms and LVEF can last 
for up to 2.5 years [55], however the mechanism of IA for DCM management is still under 
investigation and need to be elucidated further.  
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One ultimate and vital goal in clinical study is to realize diagnosis and to assess the efficacy 
of treatment at an early stage. Clinical vibrational spectroscopy, comprising of Raman 
spectroscopy and FT-IR spectroscopy, provides overall chemical information based on 
different samples e.g. body fluids, tissues and cells in a non-invasive and label-free approach, 
hence has high possibility for clinical application. [84-86] Sample preparation for vibrational 
spectroscopy is minimal, therefore the blood samples can be directly applied to clinical 
diagnosis [87]. Spectral data is often huge, thus chemometric methods comprising 
preprocessing and multivariate analysis are applied to interpret more valuable information [88, 
89]. Vibrational spectroscopy holds high possibility to study and characterize molecular 
changes directly from the patients’ blood samples in a simple, rapid and non-invasive manner, 
which makes it applicable for early diagnosis purposes [90-96]. This study is aim to 
investigate the potential of vibrational spectroscopy as a promising method to follow up the 
changes in blood plasma and serum according to IA treatment. For references, abundant 
plasma proteins as pure albumin and pure IgG were recorded as well.  
(5)  Influence  of  coronary  artery  bypass  grafting  on  spectroscopic  signature  of 
leukocytes and plasma 
Among various CVD, the most common one is coronary artery disease (CAD), also known as 
ischemic heart disease. It may affect at any age, but has a preference at older ages. In CAD, 
since there is build-up of plaque in the arteries of the heart, the coronary arteries will be 
narrowed; the blood flow to the heart muscle will be highly reduced. CAD may accompany 
with signs or symptoms of chest pain, shortness of breath, and heart attack. The view of CAD 
has changed from a cholesterol storage disease into an inflammatory disorder since last 
decades. [97, 98] Plaque or cholesterol-containing deposits and inflammation are thought to 
be the most common causative for CAD. When bacterial products or risk factors contact the 
arterial endothelium, these arterial endothelium cells will increase the expression of adhesion 
molecules which help to stick the blood leukocytes to the arterial intima. After resident in the 
inner surface of the arterial wall, the activated macrophages, T cells, and mast cells 
communicate with endothelial and smooth muscle cells, producing molecules which can 
destabilize lesions. These molecules comprise inflammatory cytokines, coagulation factors, 
proteases, vasoactive molecules, and radicals. They restrain stable fibrous caps formation, 
attack collagen in the cap, and restrain thrombus formation. Thus result in the activation and 
rupture of plaque, thrombosis, and ischemia. The atherosclerotic plaque can be treated via 
medications and surgeries. The former consists of cholesterol lowering medications, ß-
blockers, nitroglycerin, while the latter includes coronary artery bypass grafting (CABG), 
coronary stent and angioplasty. 
CABG is a surgical procedure to restore normal blood flow to an obstructed coronary artery 
by grafting bypass coronary arteries with autologous arteries or veins. There are two main 
used bypass conduits, left internal thoracic artery and the greater saphenous vein. Left internal 
thoracic artery is grafted to the left anterior descending branch of the left coronary artery, 
while saphenous-vein grafts are obtained from thigh through small incisions. [99] CABG can 
be performed via on-pump where cardiac arrest is needed and the cardiopulmonary bypass 
mimics the function of heart and lungs, or via off-pump where the heart is still beating 
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without the use of HLM. However, cardiopulmonary bypass is believed to cause a complex 
systemic inflammatory response, resulting in postoperative morbidity such as 
neuropsychological impairment, renal complications etc. [99, 100] Thus, off-pump was 
introduced to reduce postoperative complications in accordance to the use of cardiopulmonary 
bypass. [100-105] 
In this study, patients undergoing on-pump and off-pump were included. We try to 
characterize changes within the plasma and white blood cells (performed by my colleague) as 
a result of CABG via vibrational spectroscopy. 
(6) Raman spectroscopy for characterizing glycated haemoglobin in diabetes mellitus 
Diabetes mellitus (DM) is a group of metabolic disorder characterized by hyperglycemia. The 
chronic hyperglycemia disorder is often associated with long-term complications including 
different organ failures such as eyes, nerves, heart, kidneys, and blood vessels. Symptoms of 
polyuria, weight loss, polydipsia, blurred vison and polyphagia are typical for diabetes 
mellitus disorder. Besides, DM is always considered as risk factor for CVD. Hypertension and 
lipoprotein metabolism abnormalities are often accompanied with DM. Several different 
pathogenesis have been identified to involve in developing this disorder. The pathogenesis are 
insulin deficiency because of autoimmune destruction of pancreatic ß-cells called type 1 
diabetes, and insulin resistance due to abnormalities classified as type 2 diabetes. The insulin 
deficiency or resistance in the complex pathways of hormone action results in deficient 
insulin action which forms the basis of abnormalities in protein metabolism, fat, and 
carbohydrate in diabetes mellitus. In most of the diabetic cases, inadequate insulin secretion 
and insulin resistance are likely to coexist. The diabetes type of a patient can vary over time, 
and many diabetic patients should be assigned to multiple classes. The classification of DM is 
given according to their pathogenic mechanisms. Type 1 diabetic disorder results from the 
destruction of ß-cell which leads to absolute insulin deficiency. This form accounts about 5-
10% of diabetes and is often needed to be treated with insulin. Type 2 diabetes is caused by a 
combination of insulin resistance and inadequate insulin secretion, attributing for 90-95% 
diabetic disorder. Type 2 diabetes can be asymptomatic for a long time and is non-insulin 
dependent. Most type 2 diabetic patients are obese. Gestational diabetes mellitus is not clearly 
occur prior to gestation, but will be diagnosed in the second or third trimester of pregnancy. 
Other specific types compromise monogenic diabetes syndromes, diseases of the exocrine 
pancreas, drug or chemical induced diabetes and so on. [106-108]  
International Diabetes Federation has reported that there estimated to be 415 million people 
who tolerate diabetes mellitus while 193 million of them remain undiagnosed. [109] 
Currently, three recommended diagnostic tests for diabetes mellitus are using worldwide: 
fasting plasma glucose (FPG) value, 2h plasma glucose (2h-PG) value during a 75g oral 
glucose tolerance test (OGTT), and glycated hemoglobin A1c (HbA1c) test. [107, 108, 110] 
Someone will be diagnosed as having diabetes if fall into one of the following criteria: (1) 
FPG ൒ 	126mg/dl (7.0mmol/l), or 2h-PG ൒ 	200mg/dl (11.1mmol/l), or HbA1c ≥ 6.5% 
(48mmol/mol), or hyperglycemic symptoms and random PG ൒ 	200mg/dl(11.1mmol/l). 
[108, 110] The former two tests are based on plasma glucose criteria, which quantify blood-
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glucose values directly and remain as the ‘gold standard’ for diagnosis and monitoring 
diabetes mellitus [111]. The HbA1c test is based on glycated proteins, which reflects an 
average value of blood glucose concentration for last 120 days. [111, 112]  
Most proteins react with sugars without the involvement of enzymes, termed as non-
enzymatic glycation. [113] Evidences have emerged to show the potential role of non-
enzymatic glycation of proteins, or Maillard reaction, in the pathogenesis of chronic diabetes 
complications. [114] Non-enzymatic glycation of proteins are mainly divided into three 
stages: early stage, intermediate stage and late stage. Early stage glycation firstly involves the 
formation of unstable reversible aldimine compound (the Schiff base) resulting from reaction 
between reducing sugar (mainly glucose, or fructose, pentose, mannose, ascorbate, galactose, 
xylulose) and a free amino group of molecules, secondly the unstable Schiff base will be 
arranged into a stable irreversible ketoamine (Amadori product). At intermediate glycation 
stage, Amadori product degrades into a range of carbonyl compounds through oxidation and 
dehydration reactions, these carbonyl compounds are more reactive than the reducing sugars 
and act as propagators reacting with free amino groups of proteins. At late glycation stages, 
advanced glycation end-products will be formed through oxidation, dehydration and 
cyclization reactions between the propagators gained from intermediate stage and free amino 
groups. Advanced glycation end-products accumulate on long-lived proteins and will cause 
damage to the tissues. Measurements on early glycated proteins can estimate the mean plasma 
glucose over a time period and control the individual’s metabolism, while measurements on 
intermediate and late glycated products can be used to investigate the relationship between 
them and tissue modifications. Early-stage glycation products include HbA1c and glycated 
albumin (GA). [112] Glycated proteins do not require overnight fasting, thus are not affected 
by short-term lifestyle changes and are less variable among individuals. [111] 
HbA1c is formed by the non-enzymatic reaction between glucose and N-terminal valines 
residues in one or both of hemoglobin ß-chains. [111-113, 115] HbA1c test has shown its 
clinical significance for assessing glycemic control and predictive value for diabetes 
complications [116], thus has been suggested to be performed routinely including initial 
assessment and continuing care for diabetic patients. Currently, there are several methods 
used to determine HbA1c, mainly employing either ion charge differences or structural 
characteristics. The former class compromises ion exchange chromatography by high 
performance liquid chromatography (HPLC) and electrophoresis. Ion exchange 
chromatography is based on the exchange of charged ions between mobile phase and 
stationary phase which is covalently attached by charged ligands. Due to less positively 
charged at neutral pH environment and less strongly binding to the negatively charged resin, 
glycated hemoglobin components will elute before the unglycated fraction. Electrophoresis 
separates the fast hemoglobins towards cathode by applying electric potential across support 
medium. However, these charge-based techniques are sensitive to environment (temperature, 
pH), sample-storage conditions and interference from clinical factors (uremia, ethanol 
ingestion). Structural characteristics based methods include affinity binding/chromatography 
and immunoassay. Boronate-affinity chromatography separate HbA1c from Hb solution 
resulting from the esterification reaction between cis-diols of glucose and boronic acid. 
Immunoassay determines HbA1c by employing monoclonal or polyclonal antibodies to 
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recognize glycated amino acids of ß-chain. [111] Immunoassay is expensive and has lower 
values with respect to HPLC. [112]  
In order to solve the aforementioned disadvantages of the existing approaches for HbA1c 
determination, optical approaches are believed to be good alternatives. These optical 
techniques include Raman spectroscopy, infrared absorption spectroscopy, photoacoustic 
spectroscopy, optical coherence tomography and polarization spectroscopy. Promising results 
utilizing optical methods have been shown to measure blood glucose non-invasively, [111] 
paving the way to probe HbA1c in blood-based samples. Among the photonic methods, 
Raman-based spectroscopic methods seem to be the most promising one to be used in clinic. 
Ishikawa’s group have employed surface-enfacement resonance Raman spectroscopy for 
sensitive and specific detection of HbA1c [117]. However, this surface-enfacement resonance 
Raman spectroscopy has difficult to quantify HbA1c precisely. Barman and his colleagues 
have shown the possibility of DCDR to investigate HbA1c within a physiological range with 
high accuracy and reproducibility. [118] Raman spectroscopy has also been used to monitor 
the glycosylation status of proteins and determinate HbA1c in clinical cohorts. [119]  
To pave Raman spectroscopy for HbA1c determination into clinical routine test in reality, 
systematic study about the quantification of HbA1c consisting control, healthy and diabetic 
cohorts is needed. So far, Raman spectra reflect the average HbA1c degree over many red 
blood cells. However, difference in the measured red blood cells (RBCs) will affect the 
HbA1c values. It will have more sense if HbA1c value can be interpreted on single RBC 
level. In this thesis, we try to explore the potential of Raman spectroscopy to characterize 
HbA1c in diabetic patients, correlate Raman signal with clinical HbA1c values, and 
characterize HbA1c value on single RBC level. 
1.3 Blood	as	an	easy	accessible	body	fluid	sample	
Blood, one of the most common body fluids, not only contains lots of proteins, lipids, sugars 
and DNA, but also is convenient to be collected even without any interventional procedures 
and can be performed easily worldwide. In addition to its fundamental involvement in human 
function which reflects one’s physiological and pathological conditions, blood - particularly 
plasma and serum - represents an ideal sample for the diagnosis of disease. Blood is often 
referred to ‘liquid organ’, this is due to its complexity of many different components with 
very diverse properties. Blood is mainly separated into two parts according to sedimentation: 
blood cells - which represent about 45% volume of entire blood and are primarily produced in 
the bone marrow; and blood plasma - the liquid portion of blood representing approximately 
55% volume of the entire blood. [11] Blood cells are slowly differentiated from homogeneous 
pluripotent stem cells into two different precursor cells at the fetal stage - lymphoid precursor 
cells and myeloid precursor cells. Subsequent in the adult stage, these two precursor cells will 
be further developed into adult blood cells such as different lymphocytes, thrombocytes, 
leukocytes and erythrocytes. [10, 11] Adult blood cells mainly contain three types: 
erythrocytes or red blood cells (RBCs), leukocytes or white blood cells (WBCs), and 
thrombocytes or platelets. They are different in size, shape, lifetime, concentration and 
functionality. An overview of blood sample is shown in Figure 1.  
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Figure 1    Overview of blood components. [10, 11] 
Blood plasma contains many dissolved components which show different functions. These 
components include water, mineral salts, ions, low molecular weight components, high 
molecular weight components, gases in soluble form and metabolites. Among the various 
components in blood plasma, plasma proteins are the most complex one exhibiting various 
structural properties and functions. Plasma proteins are classified into different categories: 
classical plasma proteins from solid tissues and circulating in plasma are secreted by the liver 
and intestines, special immunoglobulins class with their extraordinary complexity, ‘long-
distance’ receptor ligands including classical peptide and protein hormones such as insulin or 
erythropoietin, ‘local’ receptor ligands comprises cytokines and short-distance mediators,  
temporary passengers such as lysosomal proteins, tissue leakage products containing proteins 
released from cell death or cell damage. The lifetime of plasma proteins strongly depend on 
the molecular weight regulated by the filtration cut-off of the kidney: a small size below the 
filtration cut-off of the kidney brings short lifetime in plasma such as ‘local’ receptor ligands, 
whereas the large size protein presents longer in plasma such as ‘long-distance’ receptor 
ligands. Plasma proteins play a wide variety of functions: blood coagulation and fibrinolysis, 
the complement system, the immune system, enzymes, inhibitors, lipoproteins, hormones, 
cytokines and growth factors, transport and storage, and additional proteins. The main 
difference between blood plasma and blood serum is the absence of clotting factor in serum, it 
means that blood serum is blood plasma without fibrinogens. Plasma proteins cover at least 
10 orders of magnitude of concentration range, comprising high-abundance serum albumin 
with 35-50݉݃/݈݉ representing approximately 55% plasma proteins, coagulation factors with 
1݉݃-1μ݃/݈݉, cytokines in the range of 100-1݌݃/݈݉, and low abundant interleukin-6 of only 
few ݌݃/݈݉ . The extraordinary wide concentration range brings the challenge to isolate, 
identify and characterise those low-abundance blood plasma proteins. Theoretically, any 
protein in the body can become a blood plasma protein as least temporarily. [120] Thus blood 
plasma or serum is a very promising solution to identify biomarkers for disease diagnosis and 
therapeutic monitoring.  
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Since blood plasma or serum is such a complex specimen containing unique biochemical 
information from various biomolecules, techniques to detect or discover plasma or serum 
biomarkers which relate to the disorder conditions are needed and in high demanded, 
especially those techniques which are rapid, label-free, little or no further sample 
preparations. Vibrational spectroscopy, including Raman spectroscopy and FT-IR 
spectroscopy, is such a method which conform the need of blood specimen for the clinical 
application.  
1.4 Vibrational	spectroscopy	as	a	powerful,	non‐destructive	
analysis	tool	
1.4.1 Mechanisms	of	vibrational	spectroscopy	
Light is an electromagnetic wave, composing of two perpendicular vectors: an electric vector 
ܧ  and a magnetic vector ܪ  which two are both perpendicular to the direction of light 
propagation. Thus, the electric vector ܧ, the magnetic vector ܪ, and the direction of light 
propagation are perpendicular to each other. [121] When light interacts with matter, different 
phenomenon will occur, such as absorption, reflection, and scattering. [10] In other words, 
when the electric field of this electromagnetic wave interacts with matter, the energy of light 
can be absorbed, reflected or scattered. From modern physics, we know that light contains 
inherent energy, which is expressed as following: 
ܧ ൌ ݄ ൈ ݒ																																																																																																																																			Equation	1 
Where ݄ is Planck constant. ݒ is the frequency of light, which is inversely proportional to the 
wavelength. 
All existing matter is made up of atomic or molecular structure with different and unique 
energy-states. To study the different energy states, the transition processes between them are 
investigated. This formed the study field of spectroscopy where the radiation of various types 
are analysed. The energy between transition processes is expressed as: 
∆ܧ ൌ ݄ ൈ ∆ݒ                                                                                                              Equation	2 
The term of wavenumber is more frequently used in spectroscopy, and defined as the number 
of waves contained in one unit length, and expressed as:  
ߣ ൌ ௖௩	                                                                                                                          Equation	3 
Where ߣ is wavelength. ܿ is the velocity of light. 
The electromagnetic waves contain many different wavelengths, so the energy between 
different transitions can be of different range, from 10ସܸ݁ to 10ି଺ܸ݁. [122] When consider 
of biological sample, vibrational energy of molecular structure with the typical order of 
10ିଵܸ݁ is preferred. There are two important methods to observe vibrational spectra: Raman 
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spectroscopy and infrared spectroscopy. Molecular vibrations are motions that the lengths of 
the chemical bonds and the angels between the atoms change periodically in time.  
Depending on the symmetry of the molecule, the molecular vibration can be active or 
forbidden in the Raman or infrared spectrum. [123] Raman active vibration occurs when the 
molecular polarizability is modulated by the normal vibration, and expressed as: 
ቀడఈడ௤ቁ଴ ് 0																																																																																																																																			Equation	4 
Where ߙ denotes the molecular polarizability. ݍ means the normal coordinate describing the 
atomic motions during a normal vibration. 
Infrared active vibration happens if there is a modulation of molecular dipole moment by 
vibration, and donated as: 
ቀడఓడ௤ቁ଴ ് 0																																																																																																																																			Equation	5 
Where ߤ	is the molecular dipole moment.  
Since the mechanisms of Raman and infrared spectroscopy are distinct, when the light quanta 
interact with the molecules, these two spectra can provide complementary images of 
molecular vibrations. In many of the analytical spectroscopic studies for biological samples, 
both of these two spectroscopic methods are employed.  
The principal mechanisms for the vibrational states and the energy involved for infrared and 
Raman transitions are shown in Figure 2. In infrared absorbance (Figure 2 (a)), molecules 
absorbs certain amount of incident light quanta, i.e. ݄ߥ଴, and are transited from the lower 
vibrational ground state to the upper vibrational excited states. IR absorption is frequently 
recorded by transmission ܶ - the intensity ratio of the transmitted light ܫ and incident light ܫ଴, 
or as absorbance ܣ where ܣ	 ൌ 	݈݋݃	 ቀூబூ ቁ.	As known from Equation 2, the absorbance band is 
proportional to the energy difference between the vibrational ground state and excited states. 
The intensity of absorbance band can be explained by the Lambert-Beer law: 
ܣ	 ൌ 	ߝܿɭ                                                                                                                      Equation	6	
Where ߝ is the absorption coefficient, which is dependent on ሺడఓడ௤ሻଶ. ܿ donates the molecular 
concentration. ɭ is the pathlength of the interaction between light and sample.  
The principle of Raman Effect is depicted in Figure 2 (b). When a light quanta ݄ݒ଴hits a 
molecule, two scattering processes will be observed: elastic scattering or Rayleigh scattering 
where the scattered light has the same energy as the incident light, and inelastic scattering or 
Raman scattering where the scattered light have energies higher or smaller than the 
vibrational transition energy. According to Boltzmann’s law, most molecules prefer to sit at 
their vibrational ground state at room temperature, only a few are in the vibrational excited 
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states. Thus during Raman process, the probability to transfer the molecule from the 
vibrational ground state into the higher vibrational state is much higher than to transfer the 
molecule from a vibrational excited stage into a lower vibrational state. The former is named 
Stokes Raman and the latter is called anti-Stokes Raman. As shown in Figure 2 (b), the 
intensity of Stokes Raman is higher than the anti-Stokes Raman. Therefore in most cases, if 
not required especially, the recorded Raman spectra are Stokes Raman spectra. Stokes Raman 
intensity is descripted classically as following: 
ܫ௦௧௢௞௘௦ 	ൌ 	ܿ݋݊ݏݐܽ݊ݐ	 ൈ	ܰ	 ൈ ܫ଴ 	ൈ 	ሺߥ଴ 	െ	ߥ௩௜௕ሻସ 	ൈ 	൤ቀడఈడ௤ቁ଴൨
ଶ
                                Equation	7 
Where N is the number of molecules, ܫ଴ is intensity of incident light. ߥ଴means the frequency 
of incident light. ߥ௩௜௕express Stokes Raman frequency. 
      
Figure 2    Principles of the infrared vibrational transition (a) and the Raman vibrational transition (b). 
1.4.2 Biomedical	vibrational	spectroscopy		
From above, it is clear that the principles for IR and Raman vibrations are different. They 
deliver complementary information on molecular vibrations and totality of molecule 
vibrational modes if being used together. Actually, these two spectroscopic modalities have a 
long history. The first IR experiment was performed by Herschel in 1801 and the first Raman 
Effect was discovered by Raman in 1928. [124, 125] These two modalities have been 
significantly improved for the study of biological molecules after the advent of laser Raman 
spectroscopy in early 1960s and FT-IR spectroscopy in late 1970s. The vibrational 
spectroscopic methods were moved another big step forward by the combination of the 
powerful computer and advanced chemometric methods. Thus since last two or three decades, 
FT-IR and Raman spectroscopy have become more interested and favourite methods to study 
the complex biological systems based on cells, tissues and body fluids, reflecting the changes 
according to pathological processes. Generally speaking, the variation of pathological 
processes is usually accompanied by changes in biochemistry of cells, tissues, or body fluids. 
These biochemistry changes can be ideally captured via vibrational spectroscopy, even before 
morphological and systemic manifestation diagnosed by conventional methods.  
Keep in mind, IR and Raman spectra of biomedical materials are the expression of the total 
chemical and biochemistry composition. They show the active vibrational modes of all 
constituents in the complex biological mixture simultaneously in one single experiment. 
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Therefore, the complex superposition of the characteristic Raman signals or IR absorption of 
all constituents in biological samples will result in spectral features. These spectral 
fingerprints have a huge amount which is potentially useful for diagnostic purposes, thus form 
another ‘OMICS’ discipline in life science which deal with the complex biological system in 
entirety. Therefore, vibrational spectroscopy holds high potential to diagnose dysfunction or 
disease by spectral biomarkers in rapid, label-free, non-destructive, high-throughput way. 
There are good reviews about medical vibrational spectroscopy [85, 124, 126-130] which 
include various biomedical applications such as cancers, diabetes, arthritis, neurodegenerative 
diseases, cardiac diseases, kidney stone etc. Biomedical vibrational spectroscopy can be 
mainly fall into two categories: (1) spectral analysis of extracted body fluids or excised tissue, 
either ex vivo or in vivo; and (2) spectral imaging of extracted body fluids or excised tissue ex 
vivo, or spectral imaging in vivo. From the perspective of the medical doctor, biomedical 
vibrational spectroscopy can be summarized into following areas: (1) vibrational clinical 
chemistry, which analyse the spectra of analytes; (2) vibrational pathology, which show 
cytopathology and histopathology in spectral way; (3) vibrational radiology, which use 
vibrational radiation source for biomedical imaging; (4) vibrational spectroscopy beyond 
direct disease control, like monitoring the interactions with drugs.  
Even though cells and tissues are the main samples for biomarker discovery at the beginning 
of biomedical vibrational spectroscopy [84], nowadays the study focus has been expanded to 
body fluids benificial from its easily accessibility and minimal invasiveness. These 
advantages are especially superior for large studies. Body fluids associate strongly with 
dysfunction of cells and tissues, these dysfunction manifests on the biochemical difference 
from protein, lipid, carbohydrate, and nucleic acid. Regarding body fluids, due to the ease of 
availability and repeatability, blood and its components are the most frequent and convenient 
used sample. Blood presents in all body organs and contains a huge range of proteomes from 
surrounding cells and tissues. 
Biomedical vibrational spectroscopy, especially with the use of the most common body fluid 
such as blood and its components, will revolutionise the current clinical environment into a 
more rapid, label-free, non-invasive, non-destructive, cost-effective and automatic way for 
diagnostic purposes, which can highly reduce the rising global disease burden. 
1.5 Aims	
My Ph.D thesis aims to cover all aspects from technical development by using small amount 
of blood sample for vibrational spectroscopic analysis to the demonstrations for the potential 
of vibrational spectroscopy to investigate age-related diseases. The thesis can be mainly 
divided into three topics: (1) technical development by using blood sample for spectroscopic 
analysis; (2) application of vibrational spectroscopy to diagnose and follow-up treatment of 
cardiac diseases; (3) applying Raman spectroscopy to characterize glycated haemoglobin in 
diabetes mellitus for diagnostics.  
Therefore, different specific sub-projects are involved: (1) Quality control of blood specimen; 
(2) Vibrational spectroscopic investigation of blood plasma and serum by drop coating 
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deposition for clinical application; (3) Vibrational spectroscopic differentiation of patients 
suffering from various cardiac diseases; (4) Immunoadsorption therapy follow-up for dilated 
cardiomyopathy using vibrational spectroscopic methods; (5) Influence of coronary artery 
bypass grafting on spectroscopic signature of leukocytes and plasma; (6) Raman spectroscopy 
for characterizing glycated haemoglobin in diabetes mellitus.  
For each sub-projects, individual aims are pursued: 
(1) To investigate the spectral changes and to check the quality of blood specimen due to 
prolonged waiting time delays.  
(2) To understand the redistribution of plasma proteins in the dried droplet, and to determine 
best measurement principle to capture all chemical variations and components from dried 
plasma droplet.  
(3) To investigate the differentiation of different cardiac diseases, and to study the differences 
between cardiac condition and healthy condition.  
(4) To interpret longitudinal changes in dilated cardiomyopathy according to 
immunosdsorption therapy. 
(5) To characterize spectral changes within WBCs (performed by my colleague) and plasma 
due to CABG surgery. 
(6) To characterize glycated haemoglobin via Raman spectroscopy, particularly to investigate 
glycated haemoglobin value on single red blood cell level. (experiments was performed by 
master student) 
To answer the questions and challenges above, the topic of my PhD thesis is to investigate 
and characterize the potential of vibrational spectroscopy for the stratifying patients of 
different diseases using minimal amounts of blood samples.  
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2 Materials	and	Methods	
2.1 Blood	samples	collection	
Blood samples were collected for patients and healthy donors, respectively, after giving 
informed consent (Ethic number: 4736-04/16; 4004-02/14; 3558-09/12; 3558-08/12). For 
blood samples from patients, venous blood were collected onto EDTA monovette for plasma 
or serum monovette for serum (Sarstedt, Germany) by our collaborating doctors and then 
transferred to our lab for further sample preparations. Venous blood from healthy donors were 
collected onto respective monovette for EDTA plasma or serum (Sarstedt, Germany) in our 
lab by trained colleagues, or by collecting capillary blood from the fingers onto minivette for 
EDTA plasma (Sarstedt, Germany) via Lancets by myself. The capillary blood from healthy 
donors was collected for glycated hemoglobin study, while venous blood from both healthy 
donors and patients was recruited for other projects.  
2.2 Blood	samples	preparation	
2.2.1 Centrifugation	
Blood sample was separated into different components e.g. plasma or serum, RBCs and 
WBCs via centrifuge. Centrifuge is a widely used device to separate particles from studied 
solution. Inside the centrifuge, a rotating unit called rotor has fixed holes which are fixed to 
certain angel. Sample tubes will be placed into the holes and the sample will be separated 
when the motor is spun. Centrifuge is used in balance, meaning that the rotor holes at opposite 
directions need to be used simultaneously. Centrifuge is based on sedimentation principle. At 
certain centrifugal force, the sedimentation velocity is proportional to the particles’ size and 
the difference between the densities of particles and liquid. Due to centrifugal acceleration, 
the denser particles inside the sample tube will settle down to the bottom of the tube whereas 
the low-dense particles rise up to the top. [131]  
The centrifuges used in this thesis are Universal 320R from Hettich and miniSpin from 
Eppendorf. Collected blood was prepared into different components according to our 
respective SOPs, more details about sample preparations will be given below.  
2.2.2 WBCs	isolation	
Mix 4݈݉ 10ݔ BD lysis with 36ml Ampuwa water; pipette 4݈݉ blood into a falcon, add 40݈݉ 
1ݔ  BD lysis buffer into the blood falcon and incubate about 10݉݅݊ at room temperature 
(ܴܶ ); centrifuge the incubated sample (5݉݅݊ , 300݃ , 150݉݉  rotor, ܴܶ ); disregard the 
supernatant carefully; add 1݈݉ phosphate buffered saline (PBS) into the remaining sample, 
mix gently; add 39݈݉ PBS into the sample and mix gently; centrifuge again (10݉݅݊, 300݃, 
150݉݉ rotor, ܴܶ); remove supernatant; add 1݈݉ PBS.  
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2.2.3 RBCs	isolation	
Centrifuge the collected EDTA blood ( 2000ݎ݂ܿ , 10݉݅݊ , 20°ܥ ); remove plasma and 
leukocyte buffy coat; add one fourth volume of PBS into monovette, mix gently and transfer 
the solution into a new falcon, add one fourth volume of PBS into monovette again, mix 
gently and transfer the solution into the falcon, centrifuge (2000ݎ݂ܿ, 5݉݅݊, 20°ܥ); discard the 
supernatant, add double volume of PBS into the falcon, centrifuge (2000ݎ݂ܿ, 5݉݅݊, 20°ܥ); 
redo the last step once. 
2.2.4 Plasma	/	serum	isolation	
Centrifuge EDTA monovette and serum monovette according to respective parameters 
(plasma: 2000ݎ݂ܿ, 10݉݅݊, 20°ܥ ; serum: 2500ݎ݂ܿ, 10	݉݅݊, 20°ܥ ). After centrifugation, 
aliquots of plasma and serum were stored at െ80°ܥ for further use. 
2.2.5 Glycated	haemoglobin	incubation	
Add PBS and 10μܯ  ampicillin solution to glucose solution with different concentrations 
(0݉ܯ, 5݉ܯ, 30݉ܯ, 50݉ܯ, 60݉ܯ, 70݉ܯ, 90݉ܯ), adjust pH of the mixed solution around 
7. Then add the isolated RBCs of 50% haematocrit to the mixed solution with equal volume, 
and incubate in an incubator with 160ݎ݌݉ at 37°ܥ for24݄. 
2.2.6 Blood	smear	
Pipette 7ߤ݈ EDTA blood onto one side of a clean CaF2 slide. Fix the CaF2 slide, and hold a 
clean glass slide at the opposite side between 30 െ 60°. Gently forward the glass slide to the 
blood drop with fixed angle. Once the glass slide reaches the blood drop, stop few seconds for 
it to spread. Pull the above glass slide at the same angle towards the opposite direction of the 
blood drop gently till it reaches the end of the CaF2 slide. After finishing blood smear, keep 
the slide under sterile hood about 30݉݅݊ for drying. 
2.2.7 Sample	preparation	for	vibrational	spectroscopy	
Before spectral measurements, thaw aliquots of plasma or serum to room temperature with ice 
and deposit	1ߤ݈ sample on CaF2 slide and keep under sterile bench about 30݉݅݊ for drying. 
For IR measurement, dilute plasma and serum samples with Milli-Q water in a ratio of 1:10. 
deposit 1ߤ݈ diluted sample onto a CaF2 slide and dry. Prepare RBC sample via blood smear as 
shown above. 
2.3 Vibrational	spectra	collection	
For spectroscopic measurements, the experimental set-up can be mainly separated into three 
components: radiation light source, analyser, and detection system. [122] The studied sample 
will be placed in the analyser. According to the specific application, combination of different 
light source, different analyser and different detection system will be utilized.  
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2.3.1 Raman	spectroscopy	
2.3.1.1 Confocal	microscopy	
Confocal imaging was firstly introduced in 1957 by Marvin Minsky. [132] The principle set-
up of a confocal microscope is shown in Figure 3. The point light source (usually laser) is 
focused into the sample plane via an objective; after light-matter interaction, the back-
scattered signal is collected by the same objective which guides and focuses the collected 
signal through a pinhole in front of the detector (usually charge-coupled device (CCD) 
detector). Confocal microscopy focuses the light at two positions - the light source as a point 
and the pinhole in front of detector, the name ‘confocal’ stands for this configuration. 
Confocal microscopy ensures the detection of signal only from the image focal plane, thus 
highly reduces the unexpected background from the out-of-focus light. In other words, 
confocal microscopy improves image contrast and spatial resolution greatly. By choosing 
pinhole with smaller diameters, the lateral resolution of confocal microscopy can be 
enhanced, but the detection efficiency will be decreased. Thus pinhole size and detection 
efficiency should be used in compromise. 
 
Figure 3    Principle setup of confocal microscope. [133] 
When combining confocal microscope with Raman spectrometer, the so-called confocal 
Raman microscope is adverted. Two Raman systems are used in this thesis - WITec alpha300 
and Renishaw inVia Qontor. 
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2.3.1.2 WITec	alpha	300	Raman	microscope	
 
Figure 4    Setup of WITec alpha300 Raman microscope. [133] 
Setup of WITec alpha300 Raman microscope is shown in Figure 4. This Raman microscope 
consists of two laser sources (532݊݉ Toptica Photonics AG, 785݊݉ Toptica Photonics AG), 
fibers (single-mode and multi-mode), upright microscope, spectrometer (UHTS 300, WITec, 
Germany) and CCD detector (Andor iDus, Oxford Instruments, United Kingdom). Laser is 
guided to the objective of the upright microscope through single-mode fiber. The back-
scattered light from the sample plane is focused back to the same objective, and then the 
Rayleigh light will be filtered out by the filterset. Later on, the filtered Raman light will be 
focused on the multi-mode fiber and sent to the grating-based spectrometer, finally detected 
by CCD detector.  
2.3.1.3 Renishaw	inVia	Qontor	Raman	microscope	
 
Figure 5    Setup of Renishaw inVia Qontor Raman microscope. [134] 
Figure 5 shows the set-up of Renishaw inVia Qontor Raman microscope. This system consists 
of two laser sources (532݊݉ RL532C Renishaw, 785݊݉ RL785 Renishaw), filterset, grating 
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diffraction-based spectrometer, CCD detector and Leica upright microscope. Laser excitation 
will be expanded and guided to the sample on the focus of the microscope, then the back-
scattered light will be sent to the Rayleigh rejection filters to filter out Rayleigh light and the 
remaining Raman light will be focused on the slit and collimated to the diffraction grating of 
the spectrometer, finally the dispersed Raman signal is focused onto the CCD detector.  
2.3.1.4 Raman	data	collection	
In this thesis, laser with excitation wavelength around 785݊݉ in WITec alpha 300 Raman 
microscope was used to measure blood plasma and serum for most of the studied projects, 
except for the glycated haemoglobin project which was measured on RBCs by using 
Renishaw inVia Qontor Raman microscope with 532݊݉ excitation laser. 
For the first 5 studies, Raman spectra were collected in back scattering geometry by WITec 
system using 785݊݉ radiation with about 175ܹ݉  laser power on the focal plane, the 2ݏ 
scatter spectrum were collected by 20ݔ objective with 0.8 numerical aperture. Blood samples 
were recorded in triplicates (3 batches) from three different aliquots on three different days. 
For albumin and IgG, average Raman spectra were calculated from 6 and 5 random points on 
the dried droplet respectively. The Raman spectra were collected from 20 different positions, 
10 random from the central zone and 10 random from the outer ring.  
For glycation haemoglobin study, heme structure changes due to glycation, Renishaw inVia 
Qontor with 532nm laser was used since heme is resonant at this wavelength. Raman spectra 
were recorded via a diffraction grating of 1800	lines/mm with 1ܿ݉ିଵ  spectral resolution 
over the spectral range of 200 െ 2200cmିଵ. Objective (Leica N plan EPI 50×0.75 N.A. BD) 
was used to guide the laser at the sample plane focus, and to gather the scattered Raman 
signal to the CCD detector. An average laser power of 4.5mw was on the focus of the sample 
plane. 200 RBCs were chosen to measure with 5s integration time. 
2.3.2 FT‐IR	spectroscopy	
2.3.2.1 Michelson	interferometer	
 
Figure 6    Principle schematics for Michelson interferometer. [135, 136] 
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Since most FT-IR spectrometer is based on Michelson interferometer, principle of this 
interferometer will be described (see Figure 6). Light emitted from light source is split into 
two beams after striking the beamsplitter (commonly 50% - 50% beamsplitter). These two 
beams strike a fixed mirror and a moving mirror, respectively, then reflected and recombined 
at the same beamsplitter again. At each position of the moving mirror, a signal will be 
detected by the detector. By changing the position of the moving mirror, an interference 
pattern will be generated during the movement. If the moving mirror is moved ௫ଶ, an optical 
pathlength difference of ݔ is induced (double by the reflection). If the light source emits light 
with a spectrum ܣሺߥሻ, the light intensity obtained by the detector is  
ࡵሺݔሻ ൌ 	׬ ܣሺݒሻܿ݋ݏଶ ቀ௫గ௩௖ ቁ ݀ݒ
ஶ
଴ ൌ 	ቀଵଶቁ ׬ ܣሺݒሻ ቂ1 ൅ cosሺ
ଶ௫గ௩
௖ ሻቃ ݀ݒ
ஶ
଴                         Equation	8 
Where ݒ is the frequency of the light, ܿ is the velocity of light. 
Expression ܬሺݔሻ 	ൌ 	 ቀଵଶቁ ׬ ܣሺݒሻ cosሺ
ଶ௫గ௩
௖ ሻ ݀ݒ
ஶ
଴  is called interferogram. Absorbance at each 
position infers each wavelength (or wavenumber). Interferogram is the signal recorded at all 
positions of the moving mirror during one periodical movement. Thus an interferogram 
contains spectrum from all measured wavelengths (or wavenumber).  
Spectrum ܣሺߥሻ can be calculated from ܬሺݔሻ with Fourier transform algorithm as shown in 
Equation 9, and this gives the name FT-IR for this kind of ‘Fourier transform Infrared 
spectrometer’. [135] 
ܣሺߥሻ ൌ 	׬ ܬሺݔሻ cos ቀଶ௫గ௩௖ ቁ ݀ݔ
ஶ
଴ 				                                                                               Equation	9	
FT-IR spectrometer does not use a slit to limit the light to be detected, it can record all light 
reaching the detector, thus produces higher signal-to-noise information. FT-IR improves the 
sensitivity of small absorptions and details in the spectrum of a sample such as the case of 
protein. Commercially, a laser will be installed into an FT-IR spectrometer served as the light 
source for the interferometer. The laser-source interferometer can measure precise positions 
of the moving mirror, and the laser is also a reference for precision and accuracy of the 
infrared spectrometer. For reference purpose, this laser can determine the IR wavelength more 
precisely, additionally align and calibrate the spectrometer when various IR source are used. 
Thus FT-IR spectrometer is very stable for a long period, e.g. years. [136] In this thesis, FT-
IR measurements were performed with Cary 670 FT-IR spectrometer coupled with Cary 620 
microscope. 
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2.3.2.2 Cary	670	FT‐IR	spectrometer	coupled	with	Cary	620	microscope	
 
Figure 7    Setup of Cary 620 microscope and Cary 670 FT‐IR spectrometer. [137] 
Cary 670 FT-IR spectrometer (Agilent, USA) consists of mid-infrared light source, reference 
laser, interferometer, inside sample compartment and detector. Cary 620 microscope (Agilent, 
USA) includes two detectors - liquid nitrogen cooled focal plane array (FPA) imaging 
detector of 64*64 pixels and mercury cadmium telluride (MCT) spectra detector. The 
broadband mid-infrared light from Cary 670 FT-IR spectrometer is guided to the 
interferometer. The recombined beam in the interferometer will be obtained from the two 
interfering beams which are separated from the original beam. Then the recombined beam 
will be guided to the sample placed on the Cary 620 microscope. The absorbed light from the 
studied sample can be collected in transmission or reflection mode which is collected on the 
opposite or the same side as the sample plane, respectively.  
2.3.2.3 FT‐IR	data	collection	
For FT-IR measurements, blood plasma or serum droplet was focused on the sample stage of 
Cary 620 microscope and the absorbed signals were recorded by either of the two detectors in 
Cary 620 microscope.  
FT-IR spectra were recorded via Cary 670 FT-IR system over 900 െ 3900ܿ݉ିଵ with spectral 
resolution of 4ܿ݉ିଵ over 16 scans in transmission mode for both background and all studied 
samples. For DCM project, the diluted blood samples were recorded with FPA detector of 
64*64 pixels for 5 different scans. Each scan includes 4096 spectra while 1000 randomly 
chosen spectra from each scan were used for data analysis. For reference albumin and IgG, 
MCT detector with an imaging aperture size of 50μ݉ ∗ 50μ݉  was applied due to some 
technical problems of FPA detector. For other studies, the diluted blood samples were 
collected via MCT detector with 50μ݉ ∗ 50μ݉ aperture from 10 random positions at the 
center and 10 at the ring. Background was collected on sample-free substrate nearby the 
sample area per session. 
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2.4 Immunoturbidimetry	assay	
Immunoturbidimetry assay was performed by Cora Richart in clinical chemistry lab to 
quantity total IgG. Introduction about general Immunoturbidimetry method is given briefly 
below, subsequently followed by the specific Immunoturbidimetry assay used to quantify 
total IgG. 
Due to the scattering effect of biomolecules, the intensity loss of transmitted light can be 
measured by turbidimetry. By interpreting the amount of absorbed light during the 
measurement, the number of investigated biomolecules can be obtained. By binding the 
specific antibody to the interested studied antigen, the concentration of the investigated 
biomolecules can be obtained, this is called immunoturbidimetry. 
Total IgG based on plasma and serum samples was quantified with immunoturbidimetry 
according to an immunoturbidimetric assay via Architect system (Abbott, Germany) with 
9D99 Immunoglobolin G Reagent Kit (Abbott, Germany) at the institute of Clinical 
Chemistry and Laboratory Diagnostics from the Jena University Hospital. The recommended 
commercial immunoturbidimetry assay by Abbott laboratories was applied and descripted 
shortly as following: plasma/serum was incubated with buffer R1 from 9D99 
Immunoglobulin G Reagent Kit, then the incubated solution was measured as blank sample 
before adding buffer R2 from the same kit. After the measurement, concentration of total IgG 
was determined as a function of turbidity as result of the formation of immune complexes. 
2.5 Data	analysis		
The collected raw vibrational spectra consist of not only the interested fingerprint, but also 
fluctuation by other confounding factors. Chemometric methods are commonly applied to 
remove these unwanted effects and to derive biochemical information of interest from the 
complex spectra, which helps to translate vibrational spectroscopic techniques into realistic 
clinical applications.  
Chemometrics in spectral analysis mainly includes two stages: (1) preprocessing to improve 
data quality, (2) statistical modeling to withdraw biological conclusions based on spectral 
variations. Statistical modeling can be separated into dimension reduction to retrieve the most 
significant information and classification to translate spectral information to high-level 
biological knowledge.  
All data analysis included in this thesis was carried out with in-house written scripts based on 
GNU R environment [138].  
2.5.1 Preprocessing:	Raman	spectra	
The unwanted signals in Raman spectra include cosmic spikes resulting from high energy 
particles hitting the CCD detector, Gaussian distributed white noise and Poisson distributed 
shot noise, fluorescence and thermal fluctuation from CCD. [88, 139] In order to minimize 
these unwanted variabilities and to retrieve more relevant information from the sample, 
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preprocessing steps are needed. Preprocessing for Raman spectra usually includes cosmic 
spikes removal, quality check, wavenumber and intensity calibration of Raman spectrometer, 
smoothing, fluorescence background correction, normalization and other manipulations. [88, 
139-145]  
A lot of pre-processing methods and algorithms are available and used for Raman data: de-
nosing via principal component analysis (PCA) [146], Savitzky-Golay smoothing [147], 
wavelet denoising [148], or minimum noise fraction [149]; baseline correction based on user-
defined polynomial points, extended multiplicative scattering correction [150], and 
asymmetric least squares smoothing [151]; normalization to correct sample and experimental 
variables by using vector normalization [141, 143], min-max normalization [141, 143], or 
amide I/II peak normalization [152].  
In this thesis, the raw Raman data was firstly performed despike by comparing the two 
consecutively measured spectrum. The resulted spectra were wavenumber calibrated based on 
4-acetamidophenol. Then the baseline was corrected via asymmetric least squares smoothing 
[151] or sensitive nonlinear iterative peak clipping algorithm [153]. All spectra were 
truncated to reserve only fingerprint regions (600	 െ 	1800ܿ݉ିଵand 2800	 െ 	3020ܿ݉ିଵ , or 
600	 െ 	1800ܿ݉ିଵ) and then vector normalized.  
In chemometrics, it is known that the prediction of unknown dataset is often worse than the 
prediction of training data. [154] When using a statistical model to predict new dataset, it is 
needed to improve the prediction of the model. Model transfer is such a technique which can 
achieve satisfactory prediction on the unknown dataset. A model transfer was conducted by 
extended multiplicative scatter correction according to Ref.[155], which is aimed to remove 
inter-batch variations.  
2.5.2 Preprocessing:	IR	spectra	
Preprocessing for IR spectra is slightly different as for Raman spectra. It involves outlier 
removal, smoothing, baseline correction, normalization and other manipulations. [139, 142, 
143, 152, 156] In particular, the background baseline, which is mainly caused by Mie 
scattering, can be corrected via the baseline correction methods aforementioned, as well as 
differentiation coupled with Savitzky-Golay smoothing, resonant Mie scattering correction, 
etc. In this thesis, the background baseline was removed with sensitive nonlinear iterative 
peak clipping algorithm; wavenumber region was truncated to 900	– 	1800ܿ݉ିଵ  and 
2700	– 	3700ܿ݉ିଵ	within which vector normalization was performed.  
2.5.3 Dimension	reduction		
Dimension reduction can be realized by feature extraction and feature selection. Feature 
extraction works by projecting the original data onto a new basis system that better reveals the 
properties of the dataset. The coordinates on this new basis are then used as the features in the 
subsequent analysis. Often the new basis possesses a lower dimension than original dataset, 
hence a dimension reduced data is resulted from the feature extraction. Dimension reduction 
can recognize relevant pattern from the huge dataset. Popular methods for feature extraction 
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include PCA, and partial least squares. [141] Feature selection picks variables in the original 
data space that are the most significant for the classification or regression model. Common 
feature selection approaches include COVAR [157], forward feature selection [158], and 
choosing specific wavenumbers to determine spectral biomarkers [141].  
PCA was performed on our data to obtain information of the most interest. PCA aims to 
represent the variances present in the data using a smaller number of factors (called principal 
component (PC)). Mathematically, PCA is an orthogonal transformation. The PCs are 
orthogonal to each other and each represents a different variance source in the data. The 
original data is linear combination of the PCs. [146, 159, 160] 
2.5.4 Classification	or	regression	model	
Classification and regression are popularly used for diagnostics analysis, to derive disease 
levels or concentration of certain substances, respectively. In both cases, a statistical model is 
built based on a training dataset to relate the spectral information to the required high-level 
knowledge. Thereafter, a testing dataset independent to the training dataset will be used to 
validate the classifier. Common supervised machine-learning approaches to build a statistical 
model are linear discriminant analysis (LDA), support vector machine (SVM), artificial 
neural network, random forest, and partial least squares regression (PLSR). [141, 142] Sample 
size was proven to highly influence the performance of a statistical model. If appreciable, a 
sample size of 75-100 should be chosen to train classifier in order to get good precision and 
validation. [161] Besides, a robust model can be built through two stage training - firstly use 
cross-validation (CV) approach to find optimal parameters where the highest accuracy is 
achieved, secondly use the optimal parameters to build a proper classifier from the training 
dataset. [162] 
Classification algorithm including SVM and LDA were employed for our data. The 
classification models were built via two-layer cross-validation, with the aforementioned PCA 
involved in the validation loop. The inner layer was based on training data where a 10-fold 
cross-validation was conducted and the parameters were optimized according to the accuracy 
of the model. The built model was used to predict the testing data that was from a different 
batch as the training data. To be specific, the outer layer was performed through a leave-one-
batch-out cross-validation, where each batch was used once as testing data and the rest 
batches were used as training data. The model was benchmarked by accuracy of the 
prediction. In this study, the PCA-SVM model was built to classify the different IA treatment 
stages from the DCM patient, while PCA-LDA model was built to differentiate the Raman 
spectra collected from different time delays.  
To predict HbA1c values from Raman spectra based on RBCs, PLSR regression model was 
built via 2-layer cross-validation as described above: 1st leave-one-sample-out-cross-
validation, 2nd 10-fold cross-validation. The optimal components used in PLSR were chosen 
automatically when the lowest CV error was firstly achieved – according to the root mean 
squared error of prediction (RMSEP). The predictive ability of the model was validated by 
calculating R2 of the model.  
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2.5.5 Workflow	of	data	analysis	
To better visualize data analysis procedures, the workflows corresponding to Raman data and 
FT-IR data are given below.  
 
Figure 8    Workflow of Raman spectra analysis. Project number ①②③④⑤⑥, corresponding to the order of 
motivations and aims given in Section 1.2 and Section 1.5 respectively. 
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Figure 9       Workflow of FT‐IR spectra analysis. Project number ①②③④⑤⑥, corresponding to the order of 
motivations and aims given in Section 1.2 and Section 1.5 respectively. 
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3 Results	and	Discussion	
3.1 Technical	development	for	using	blood	as	sample	for	
spectroscopic	analysis	
This section demonstrates quality check of blood specimen by using drop coating deposition 
Raman (DCDR) spectroscopy, and vibrational spectroscopic investigation of plasma by drop 
coating deposition for clinical application. 
3.1.1 Quality	check	of	blood	specimen		
Sample cohort. Serum blood from five healthy donors are collected, and stored at room 
temperature before serum centrifugation. The four different storage time (called time delays 
below) are given in Table 1. From clinical chemistry, variations are observed during these 
time delays, and these changes are mainly contribution from different metabolites.  
Table 1    Information for healthy cohorts 
Donor (n) 5
Time delay (n) 4
30݉݅݊ 60݉݅݊ 120݉݅݊ 240݉݅݊ 
Mean spectra. The spectra were captured via drop coating deposition Raman (DCDR) 
spectroscopy. The mean Raman spectra of different time delays from five individual donors 
are shown in Figure 10, the well overlay mean spectra of the four different time delays 
indicate that the sample are stable during the prolong processing time, only gentle difference 
occur. To better visualise the variation, difference spectra between different time delays were 
calculated and show in Figure 11. 
	
Figure 10    Mean spectra of different time delays from five individual donors. 
Difference spectra. Variations of the time delays from serum samples are shown in the 
difference spectra (Figure 11). The changes are mainly attributed from the spectral marker 
around 800ܿ݉ିଵ , especially when comparing the difference between 30݉݅݊  and 60݉݅݊ , 
between 30݉݅݊ and 120݉݅݊, and between 30݉݅݊ and 240݉݅݊ time delays as indicated in 
Figure 11 (a, b, c). After 120݉݅݊ delay, no change is observed in spectra (Figure 11 f). Blood 
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will undergo changes if being stored for long time, these changes do not have an identical 
patterns for all individuals (see Figure 11 a, b, c, d, e), giving a hint for the role of intra-
sample variation in the changes. To verify these changes are due to time delay in sample 
preparation, PCA analysis was performed. 
 
Figure 11    Difference spectra of different time delays from five individual donors. 
PCA analysis. PCA analysis based on different time delays was calculated for individual 
donor and five donors together. PCA scatter plot were presented in Figure 12. The sera from 
the four time delays cannot be differentiated, neither for the individual donor nor for all five 
donors together. PCA analysis shows no difference due to time delay in sample preparations. 
But different PCA patterns were visible for different donors. Hence to obtain further 
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information, coefficients of measurement factors were calculated and presented later. The un-
differentiable can be due to the following reasons: (1) the biochemical difference between 
these four time delays are too small; (2) individual heterogeneity plays a role; (3) the analysis 
algorithm is not robust enough, more robust algorithm is needed to be performed on the data. 
The first two are intrinsic property, and cannot be solved with data analysis methods.  
 
Figure  12        PCA  scatter  plot  between  different  time  delays  from  five  individual  donors  and  five  donors 
together. 
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PCA-LDA model. To test the arguments presented, PCA based LDA model with leave-one 
(donor)-out cross-validation was performed on the spectra from all five donors. The PCA-
LDA model was used to cluster the collected spectra into different groups corresponding to 
different time delays. The results for the PCA-LDA model are shown in Table 2, indicating 
that the spectra cannot be grouped into respective time delays.  
Table 2    Confusion matrix of PCA‐LDA model with leave‐one (donor)‐out‐cross‐validation  
Test Predict
30݉݅݊ 60݉݅݊ 120݉݅݊ 240݉݅݊ 
30݉݅݊ 2 9 40 9 
60݉݅݊ 0 20 27 13 
120݉݅݊ 0 13 40 7 
240݉݅݊ 3 10 35 12 
Coefficients of experimental factors. In order to understand the variance further, the 
coefficients of experimental variations were calculated using ASCA method (ANOVA-
simultaneous component analysis). To explain in brief, the data matrix from recorded spectra 
was decomposed as contributions of different experimental factors as shown in Equation 10 
for all donors together: 
ܦܽݐܽ ൌ ݉݁ܽ݊	ݏ݌݁ܿݐݎܽ ൅ 	ܤܽݐ݄ܿ݁ݏ	 ൅ 	ܶ݅݉݁	 ൅ 	݀݋݊݋ݎݏ	 ൅
	݅݊ݐ݁ݎܽܿݐ݅݋݊	ሺܶ݅݉݁	&	ܾܽݐ݄ܿ݁ݏሻ ൅ 	݅݊ݐ݁ݎܽܿݐ݅݋݊	ሺ݀݋݊݋ݎݏ	&	ܾܽݐ݄ܿ݁ݏሻ ൅
	݅݊ݐ݁ݎܽܿݐ݅݋݊	ሺ݀݋݊݋ݎݏ	&	ܾܽݐ݄ܿ݁ݏሻ ൅ 	݋ݐ݄݁ݎ	݂ܽܿݐ݋ݎݏ																																																																																									 										
Equation	10	
Table 3    Contributions of individual experimental factors for five donors together 
Factors Batches Time Donors  Batches 
& Time
Batches 
% Donors
Donors 
% Time 
Other 
factors
%Var 2.26% 2.34% 14.07% 1.80% 5.05% 3.59% 70.90%
or expressed as Equation 11 for individual donor: 
ܦܽݐܽ ൌ ݉݁ܽ݊	ݏ݌݁ܿݐݎܽ ൅ 	ܤܽݐ݄ܿ݁ݏ	 ൅ 	ܶ݅݉݁	 ൅ 	݅݊ݐ݁ݎܽܿݐ݅݋݊	ሺܶ݅݉݁	&	ܾܽݐ݄ܿ݁ݏሻ ൅
	݋ݐ݄݁ݎ	݂ܽܿݐ݋ݎݏ																																																																																																																							Equation	11 
Table 4    Contributions of individual experimental factors for individual donor 
Donor Factors Batches Time Batches 
& Time
Other factors 
HD_01 %Var 7.92% 6.77% 16.03% 69.29% 
HD_02 9.29% 6.89% 22.64% 61.18% 
HD_03 9.25% 6.94% 18.60% 65.22% 
HD_04 12.80% 7.09% 23.83% 56.28% 
HD_05 4.09% 6.90% 31.05% 57.96% 
The calculations show that the most significant factor affecting the variation is other factors. 
When considering the data from the five donors together, the donors’ variation is the second 
major factor for the variation, this confirms the result from Ref [30]. Above all, coefficients of 
factors show that individual heterogeneity has second highest contribution after other factors. 
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Summary and discussion. From the results above, some minor differences can be captured 
via DCDR if prolong the time delay between blood collection and blood centrifugation, but 
donor heterogeneity is high. The PCA and PCA-LDA analysis show that the serum is quite 
stable and only few non-significant changes will occur when keeping up to 4 hours before 
centrifugation [26, 27, 34]. The variance calculation indicates that the time delay affects the 
changes of the sera in Raman spectra at a least extent, confirmed by small contribution values 
of time in Table 3 and Table 4. According to the literatures, the changes inside the blood 
under certain time delay of preparation are mainly from the small molecules in metabolites 
reflecting erythrocyte activity [21, 30, 31, 33] and from low-molecular-weight proteins [23, 
25, 28]. To observe these small metabolites or proteins, the macromolecules need to be 
depleted; otherwise the Raman spectra will be dominated by the major high-molecular-weight 
proteins such as albumin, IgG, ect. This can be a reason that the DCDR spectra are not able to 
differentiate the serum prepared with different time delays. In our study, no protein was 
removed in sample preparation, because it is very often that the interested biomarker is 
unknown in clinical application, we would like to keep the integrity of the measured specimen. 
Above all, DCDR spectra seem to have stable biochemical information from the blood 
specimen up to 4 hours delay before centrifugation. Thus it is reasonable and reliable to use 
DCDR to search biomarkers from blood specimen. To investigate the biochemistry in the 
blood specimen for time delay between blood collection and separation, other methods need 
to be conducted: depletion of the abundant plasma protein, use the sample in liquid form with 
advanced Raman spectroscopy such as stimulated Raman spectroscopy and surface-enhanced 
Raman spectroscopy, apply attenuated total reflection FT-IR method for capturing changes in 
the small proteins. Moreover, a large donor cohort also needs to be considered in further study. 
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When we use good quality blood specimen for clinical application, the sample can be 
prepared via drop coating deposition method, but further understanding about drop coating 
deposition method via vibrational spectroscopy is needed to be investigated. 
3.1.2 Vibrational	spectroscopic	investigation	of	plasma	and	serum	by	
drop	coating	deposition	for	clinical	application	
Sample cohort. Blood samples were collected from healthy donors (n=17) and patients 
(n=18). These included the patients who had different cardiac diseases, e.g. dilated 
cardiomyopathy (DCM), heart failure (HF), and coronary artery bypass grafting (CABG) 
surgery. Both plasma and serum sample were investigated. For plasma we had 7 healthy 
donors and 18 patients, for serum we had 10 healthy donors and 2 patients. 
Morphology from white light image. The typical morphology of microscopic white light 
image for dried plasma or serum droplet is shown as Figure 13. The dried droplet is separated 
into two different parts, the central zone with crystal pattern and the ring zone at the edge, 
indicated by inner and outer individually in this thesis. These two regions accumulate 
different molecules, thus to take the inhomogeneous coffee-ring effect into account and better 
represent the whole dried droplet, a measurement geometry for the samples with 10 random 
points in the inner and 10 random points in the outer was used. For plasma and serum sample 
from healthy donors measured via FT-IR spectroscopy, 5 locations are randomly chosen in 
both the inner and outer region.  
 
 
Figure 13    White  light  image of dried plasma droplet  from healthy donor,  the droplet  is separated  into  two 
parts: the central zone (inner) and the ring zone at the edge (outer), the  inner  is crystalized. The 20 red dots 
represent 20 different measurement points. 
Raw spectra collected from inner and outer. As shown in Figure 13, different 
biomolecules form different morphology of the dried droplet, which represent different 
biochemical fingerprint [37, 163-165]. To better understand the separated morphology 
difference, raw spectra comparison between inner and outer region are done and shown in 
Figure 14. From Figure 14, it is clear that the Raman signal for plasma and serum droplet in 
the outer is higher than in the inner. However, the spectra collected from inner have similar 
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Raman pattern as from outer. This is the same for the FT-IR spectra. It can be explained by 
the aggregation of biomolecules (mainly proteins with the amide bands shown in Figure 14) 
in the outer due to the coffee-ring effect which drive the particles to the ring. However, there 
are proteins remained in the inner of the droplet but with few quantities (see the raw spectra 
collected from inner in Figure 14) [37]; this can result from the suppression of coffee-ring 
phenomenon by Marangoni effect which carries the particles toward the inner [37, 42].  
 
Figure 14    Raw spectra comparison between outer  (green color) and  inner  (red color)  from Raman data and 
FT‐IR data of healthy donor (n=1). 
It is well-known that in blood plasma and blood serum, the most abundant blood protein 
albumin accounts for nearly 55% of the overall blood proteins. The second most 
predominating proteins are Ig (or antibodies), which constitutes about 38% of blood proteins. 
Within all Ig, IgG has majority contribution, attributing about 75% of Ig. It is still not clear 
about the origins for crystal-like patterns in the central part of plasma droplet. Chen and 
Mohamed suggested that the crystal-like patterns were albumin by using fluorescent 
microscopy. [166] And other researchers have suggested that the central part of the dried 
plasma droplet can be crystals combinations of proteins and salts. [167, 168] We can confirm 
presence of proteins and visualize crystal structures in inner. However, Yakhno proposed that 
the crystal patterns were salts on the gelled protein matrix. [169] The contradiction is whether 
the crystal pattern in inner is only salt but above the gelled protein matrix, or the crystal 
pattern is the combination of salt and proteins. They agree with the presence of proteins in 
inner, but disagree on the origin for crystal patterns in inner. In this thesis, I try to clarify the 
locations of abundant plasma proteins including albumin and IgG in the droplet rather than to 
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find out the origin of central crystal-like patterns via Raman spectroscopy and FT-IR 
spectroscopy.  
Preprocessed spectra. In order to find out the contributions of albumin and IgG in the 
dried droplet, Raman and FT-IR spectra from pure albumin and IgG were recorded as 
references. Figure 15 shows the corresponding Raman and FT-IR pattern of albumin and IgG. 
The inner and outer of the plasma and serum droplet share the same Raman fingerprints, 
which are mainly contributions from albumin. Besides, IgG also influences the Raman profile 
for plasma and serum droplet around 756ܿ݉ିଵ, 1240ܿ݉ିଵ, 1340ܿ݉ିଵ, and 1552ܿ݉ିଵ. The 
presence of albumin in the droplet can also be verified with the FT-IR spectra shown in 
Figure 15 (b). The vibrational spectra shown in Figure 15 confirm the presence of albumin 
and IgG not only in the ring but also in the central part of dried droplet. But the distribution of 
albumin, IgG and other proteins are inhomogeneous across the whole droplet as result of 
coffee-ring effect. The pre-processed spectra collected from inner and outer are overlaid in 
Figure 15, some differences between them can be observed. PCA analysis based on spectra 
collected from inner and outer was performed to dig out more information about the 
differences, and the results are presented in the following. 
 
Figure 15    Spectra comparison of blood droplet (inner and outer) from healthy donor, albumin and IgG. 
PCA analysis for spectra collected from healthy donors. When prepared body fluid 
sample through drop coating deposition method, the biochemical difference or similarity 
between inner and outer region of the dried droplet need to be tested before any real 
application. That means, it is very critical to choose an optimal collection protocol which can 
represent the whole dried droplet by taking the coffee-ring effect into account. In order to 
check the differentiation or similarity of the biochemical information between inner and outer 
regions, PCA analysis based on inner and outer regions from healthy donors (n=17) is 
performed and PCA scatter plots (donor, n=1) are presented in Figure 16, which shows that 
the Raman and FT-IR spectra obtained from the inner and outer regions can be distinctly 
separated into two clusters, indicating the different biochemical compositions between these 
two regions. For all healthy donors, PCA scatter plots are the same as Figure 16, results are 
not shown here. 
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Figure 16    PCA analysis of vibrational spectra of inner and outer region from healthy donor (n=1). 
To better understand the biochemical difference between inner and outer, the corresponding 
PC loadings of PCA are shown in Figure 17. From Figure 17, it is obvious that the 
biochemical difference between the inner and outer are mainly contributions from proteins, 
indicated by the typical protein Raman bands around Try (857ܿ݉ିଵ , 1208ܿ݉ିଵ ), Pro 
(857ܿ݉ିଵ), tyrosine (857ܿ݉ିଵ), Phenylalanine (1004ܿ݉ିଵ), amide I (1659ܿ݉ିଵ) and C-H 
stretching (2933ܿ݉ିଵ ); and FT-IR fingerprints around amide II (1512ܿ݉ିଵ ), amide I 
(1655ܿ݉ିଵ, 1695ܿ݉ିଵ), C-H stretching (2962ܿ݉ିଵ). The Raman pattern to differentiate the 
inner and outer is very similar for the plasma samples from all healthy individuals. This 
means that the different distribution of biomolecules in inner and outer is a common feature 
among all individuals. However, when considering serum sample with Raman spectroscopy, 
the spectral difference differentiating the inner and outer regions is inconsistent as the 
difference observed in Figure 17 (c). This is due to the different PC values regarding to inner 
and outer. For HD_01 and HD_04, outer is clustered into negative PC1 values while inner is 
clustered into positive PC1 values. Opposite clustering happens to other serum samples. The 
PC1 loading is similar for HD_01 and HD_04, but opposite to other serum samples (see 
Figure 18). For the FT-IR spectral loadings, both plasma and serum samples have similar 
biochemical difference between the inner and outer regions; these differences are mostly 
contributions from proteins.  
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Figure 17       PC  loadings of  vibrational  spectra of  inner  and outer  region  from healthy donor  (plasma: n=7; 
serum: n=10). 
 
Figure 18    PC loadings of Raman spectra of inner and outer region from healthy donor (serum: n=10). 
The PCA analysis and respective loadings in Figure 16, Figure 17, and Figure 18 indicate that 
distribution of biomolecules varies between inner and outer regions of the dried sample 
droplet. Despite it is still unclear about the pattern formation of the droplet, this drop coating 
deposition method has been used for medical diagnosis since 1950s. The traditional droplet 
evaporation research derives information from the dried droplet directly; the information 
obtained is morphology of crystal aggregates, crystal shape and size, and morphology of 
crack patterns. [170] With the increase in advanced analytical methods including Raman 
spectroscopy and FT-IR spectroscopy, more information beyond the aforementioned 
traditional droplet analysis can be interpreted from the same droplet. When combining 
44 
 
vibrational spectroscopy with droplet coating method for clinical application, one important 
issue is to find out the proper measurement positions representing the whole sample area. 
However, it needs to be less time consuming and can produce data with high signal-to-noise 
ratio. To answer this question, PCA analysis of vibrational spectra combining with drop 
coating deposition technique on different biomedical applications will be discussed. As 
examples, the following Raman and FT-IR spectroscopic data will be discussed: a DCM 
patient undergoing IA treatment, a HF patient undergoing treatment, cardiac patients 
receiving CABG surgery. 
PCA analysis of DCM patient. The DCM patient remained highly depressed (18%) LVEF 
after 9 months pharmacological HF treatment, and was recommended for IA therapy. IA 
therapy was given at five different time points (donated as stage - S), the potential of 
vibrational spectra to characterize these five different stages to follow up therapy outcome 
was studied. Here the PCA analysis for different regions of dried droplet is performed and the 
PCA scatter plots for inner region, outer ring and whole droplet of plasma and serum obtained 
via Raman spectroscopy are shown in Figure 19. The Raman spectra from different collection 
locations of the droplet form similar cluster patterns as observed in the PCA scatter plot, and 
the lowest intra-group scattering is obtained when the Raman spectra from the whole droplet 
are used, thus have a better discrimination of different IA treatment time points. For FT-IR 
spectra, data were collected from five randomly chosen mapping images, the information 
regarding inner and outer was not captured, thus FT-IR spectra are not discussed for this 
patient here. 
 
Figure 19    PCA analysis of Raman spectra of inner and outer region from plasma and serum samples from DCM 
patient underwent IA therapy. (n=1) 
PCA analysis of HF patient. HF is a rather complex syndrome in which the heart cannot 
supply enough blood to the body, resulting from various structural or functional cardiac 
abnormalities. Raman and FT-IR spectra from inner region, outer ring, and whole droplet 
based on plasma sample are used for PCA analysis, the results are shown in Figure 20. For 
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Raman data (Figure 20 (a, b, c)), the molecules located in inner, outer or the whole droplet 
can deliver the information responding to different treatment stages. But for FT-IR case 
(Figure 20 (d, e, f)), it is clear that only the spectra from inner region can separate the three 
different treatment stages, neither the spectra collected from outer region nor from the whole 
droplet can differentiate the three stages. For this case, the signal from inner region captures 
disease specific information, hence the measurement points from inner region are 
recommended. However, for serum sample, Raman data collected from these three geometry 
cannot be separated into different treatment clusters, while the FT-IR data show similar 
patterns as in Figure 20(d, e, f), results are not shown in the thesis.  
 
Figure 20    PCA analysis of vibrational spectra of inner and outer region from plasma sample from HF patient. 
(n=1) 
PCA analysis of CABG patients. When the coronary artery was obstructed due to 
arteriosclerosis or fat deposition on the wall of artery, the patients suffers from severe 
coronary heart disease. These patients usually undergo cardiac surgery, especially CABG to 
improve blood flow to the heart. To evaluate changes in the blood, plasma samples were 
collected before surgery (BS) and after surgery (AS). PCA analysis for Raman spectra and 
FT-IR spectra collected from inner region, outer ring, and whole droplet of plasma are 
represented for two different CABG patients as shown in Figure 21 and Figure 22. 
From Figure 21, it is observed that the Raman and FT-IR spectra from inner region, or from 
outer region, or from the whole droplet can separate the plasma samples regarding to BS and 
AS. For this patient, the spectra collected from just inner or outer ring are sufficient. This 
measurement geometry holds true for ten of the fifteen CABG patients, data are not showed. 
However, for the second patient, this is not true.  
When the same PCA analysis was performed to the plasma sample from the second CABG 
patient, the spectra from either inner region or outer ring perform differently to the whole 
droplet. The spectra only from the inner region or outer ring can be differentiated into two 
clusters, while the spectra from the whole droplet are not clustered into corresponding 
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separate groups. For this case, the spectra from either inner region or outer ring are suggested, 
but not the spectra from whole droplet. This geometry is applicable for other four CABG 
patients, which data are not shown. 
 
Figure  21        PCA  analysis  of  vibrational  spectra  of  inner  and  outer  region  from  plasma  sample  from  CABG 
patient I. (n=1) 
 
Figure  22        PCA  analysis  of  vibrational  spectra  of  inner  and  outer  region  from  plasma  sample  from  CABG 
patient II. (n=1) 
Summary and discussion. When a dried droplet is formed on a solid substrate, the 
distribution of different biomolecules will be separated due to the coffee-ring effect and the 
reverse Marangoni power. The microscopic morphologic image from the droplet show 
different patterns formed by different biomolecules at different regions of the dried droplet. 
The different distribution due to various biomolecules will relate to specific biochemical 
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fingerprint. This is confirmed by the spectra comparison, PCA analysis and PC loadings from 
inner region and outer ring which is show in Figure 14, Figure 16 and Figure 17 individually. 
The spectra intensity is much higher for the biomolecules from the outer ring than from inner 
zone. Even though the proteins are pre-concentrated in the outer ring via drop coating method, 
the best measurement geometry varies depending on different cases when applied for real 
biomedical applications. The consideration of whole droplet with equal collecting points from 
inner and outer is better for DCM case. But for the HF patient, FT-IR spectra collected only 
from inner is able to be differentiated into corresponding treatment stages. While for CABG 
application, the schematics of equal measurement positions from whole droplet and from 
either only inner zone or outer ring is suggested for different patients.  
When seeking biomarkers in blood sample, many studies have been performed. Since the 
abundant albumin and IgG dominate the vibrational spectroscopic signals, depletion of those 
abundant proteins can be applied if the interested biomarkers are masked by the signal of 
those abundant proteins. However, the depletion can remove some information for the 
unknown biomarkers of interest, thus the intact sample will be a more appropriate choice in 
this case. Based on the results and discussion above, when combing the vibrational 
spectroscopy to search biomarkers on plasma or serum samples, the measurement geometry 
of equal collection positions from inner zone and outer ring will be suggested. By this 
schematic, the consideration of different biomolecules in the whole sample will be included, 
and the contribution of different biomolecules can be studied when taking into account of the 
different morphology and distribution of biomolecules at different regions of the dried droplet. 
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3.2 Application	of	vibrational	spectroscopy	to	cardiac	diseases:	
diagnostics	and	treatment	control	
Based on the previous sections about technical development for using blood as sample for 
spectroscopic analysis, this section will move to the biomedical applications on cardiac 
diseases. 
3.2.1 Vibrational	spectroscopic	differentiation	of	patients	suffering	
from	various	cardiac	diseases	
Sample cohort. 18 patients undergoing different cardiac disorders were recruited in the 
study (Ethic number: 4736-04/16). One patient was diagnosed with DCM, one was 
characterized as TTC, one was HF, and other patients had different cardiac conditions which 
are not yet unblinded. One 9݈݉ EDTA blood and one 9݈݉ serum blood were collected from 
each patient. As reference control, healthy volunteers were also recruited with 7 plasma and 
10 serum samples individually.  
Vibrational spectra for cardiac patients.	 Since the 18 cardiac patients had different 
cardiac disorders, the physiopathology and clinical presentations were characterized to be 
different. The differences can influence the Raman and FT-IR spectra. Thus the mean spectra 
of Raman spectroscopy and FT-IR spectroscopy was calculated and shown in Figure 23. From 
Figure 23, it is observed that 17 cardiac patients have similar Raman profiles for both plasma 
and serum sample, except for the cardiac patient with ID CP04 which has very distinct Raman 
spectra from others. However, when considering FT-IR spectra, the distinctiveness of CP04 is 
vanished; all the 18 cardiac patients share similar FT-IR fingerprints. More information can 
be interpreted if the clinical information of these patients were known, whereas the clinical 
information is still waiting to be provided by the collaborating physician doctor.  
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Figure 23       Vibrational spectra of plasma and serum sample  from cardiac patients. Left panel: Raman;  right 
panel: FT‐IR. Top panel: plasma; low panel: serum. 
PCA analysis for cardiac patients. To better visualize the similarity and difference 
between the 18 cardiac patients, PCA analysis was performed, and the corresponding PCA 
scatter plot and PCA loadings are shown in Figure 24 and Figure 25 respectively. The 
distinctiveness of CP04 from Raman spectra was confirmed via the clusters on the left panel 
in Figure 24. The distinctiveness is mainly from the contributions of proteins as observed 
from the corresponding loadings shown in the left panel of Figure 25, where PC1 separates 
patient CP04 from others. CP01, CP02, CP03, CP05, CP16 and CP17 are grouped together 
with negative scores of PC1 and positive scores of PC2 in Figure 24 (a) and (c).; whereas 
CP06, CP15 and CP07 are clustered into one group due to negative scores of PC1 and PC2. 
For FT-IR spectra, different clusters were formed based on the FT-IR contributions as 
observed from PCA loadings shown on the right panel in Figure 25. For plasma sample, CP02 
and CP13 are quite distinct from others; while other patients are clustered closely which 
indicates the similarity among them. But for serum sample, CP11 clusters separately, CP06, 
CP07, CP13, CP15 and CP18 cluster close to each other according to negative scores of PC2 
shown in Figure 24 (d). 
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Figure 24    PCA scatter plots of plasma and serum sample from cardiac patients. Left panel: Raman; right panel: 
FT‐IR. Top panel: plasma; low panel: serum. 
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Figure 25    PCA loadings of plasma and serum sample from cardiac patients. Left panel: Raman; right panel: FT‐
IR. Top panel: plasma; low panel: serum. 
Vibrational spectra from healthy donors and cardiac patients. The 18 cardiac 
patients had different cardiac disorders, the vibrational spectra from these cardiac disorders 
and healthy donors were compared and shown in Figure 26. From Figure 26 (a) and (c), the 
difference between the healthy donors and cardiac patients based on Raman spectra are 
clearly observed while these differences are not so pronounced for FT-IR spectra in Figure 26 
(b) and (d). 
To better visualize and interpret the differences, difference spectra between healthy donors 
and cardiac patients were calculated and shown in Figure 27. The contributions to 
differentiate healthy donors and cardiac patients are mainly from proteins with the Raman 
spectra from amide III, amide I, and FT-IR spectra from amide II and amide I. Moreover, 
carotenoids play a role in the difference between the healthy and cardiac disorders indicated 
by Raman spectra around 1158ܿ݉ିଵ  and 1520ܿ݉ିଵ . [171, 172] The contribution of 
carotenoids can be due to its antioxidant properties such as scavenging free radicals like 
reactive oxygen species, lipid peroxyl radicals and nitric oxide. Carotenoids can protect the 
circulating low density lipoproteins from oxidation and decrease the number of cholesterol 
being carried into blood stream. In some studies, lycopene (member of carotenoids family) 
has shown to lower the risk of CVD through reducing serum cholesterol level. [173-175] 
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Figure 26    Vibrational spectra of plasma and serum sample from healthy donor (HD) and cardiac patients (CP). 
Left panel: Raman; right panel: FT‐IR. Top panel: plasma; low panel: serum. 
	
Figure 27    Difference spectra of plasma and serum sample from healthy donor (HD) and cardiac patients (CP). 
Left panel: Raman; right panel: FT‐IR. Top panel: plasma; low panel: serum. 
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PCA analysis of vibrational spectra from healthy donors and cardiac patients. 
Unsupervised PCA analyses were performed based on the dataset from healthy donors and 
cardiac patients. The PCA scatter performances were different based on the corresponding 
Raman (Figure 28 (a) and (c)) or FT-IR spectra (Figure 28 (b) and (d)) according to the 
contributions from respective PCA loadings on Figure 29. For Raman dataset, CP04 is very 
distinct from either the healthy donors or other cardiac patients, as indicating by the yellow-
filled circle in Figure 28 (a) and green-filled circle in Figure 28 (c). The healthy donors were 
differentiated from cardiac patients mainly due to the carotenoids, confirmed by the negative 
contributions around 1158ܿ݉ିଵ and 1520ܿ݉ିଵ shown in Figure 29 (a) and (c) [171, 172]. 
PC2 clusters health into negative scores (see Figure 28 (a) and (c)), these negative scores 
correlate with the negative bands of carotenoids in Figure 29 (a) and (c), giving a hint of 
higher presence of carotenoids in health than in cardiac patients [174, 175]. 
	
Figure 28    PCA scatter plots of plasma and serum sample from healthy donors (HD, plasma: n=7; serum: n=10) 
and cardiac patients (CP, n= 18). Left panel: Raman; right panel: FT‐IR. Top panel: plasma; low panel: serum. 
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Figure 29    PCA loadings of plasma and serum sample from healthy donor (HD) and cardiac patients (CP). Left 
panel: Raman; right panel: FT‐IR. Top panel: plasma; low panel: serum. 
Summary and discussion. CVD is various and the research to investigate CVD has begun 
long time ago and are still undergoing as hot topics. By the combination of advanced 
analytical methods such as Raman spectroscopy and FT-IR spectroscopy in combination with 
chemometric approaches, the 18 patients with different cardiac disorders are clustered into 
different groups, the PCA loading indicates different biomolecular contributions. More details 
from the studied spectral data can be interpreted if the clinical information can be provided by 
the collaborating physician doctor. When considering the healthy and CVD cohorts, 
carotenoids play a key role between these two cohorts. The less presence of carotenoids in 
CVD cohort can be an indication to characterize cardiac disorder. 
This study demonstrates the potential of vibrational spectroscopy to characterize different 
cardiac conditions. Two studies of different treatments response to different cardiac disorder 
will be introduced and discussed in the following sections, these include the follow-up of 
immunoadsorption therapy in dilated cardiomyopathy using vibrational spectroscopic 
methods in section 3.2.2 and vibrational spectroscopic investigation of patients undergoing 
coronary artery bypass grafting in section 3.2.3. 
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3.2.2 Immunoadsorption	therapy	follow‐up	for	dilated	
cardiomyopathy	using	vibrational	spectroscopic	methods	
Patient characteristics. After informed consent (Ethic number 4736-04/16), a 52-year old 
female patient was selected for this study. DCM was characterized by severely depressed 
LVEF (15%) via echocardiography and left ventricular angiography. CAD was excluded 
through coronary angiography method. The patient was treated with completion of 
pharmacological HF treatment for 9 months, but LVEF still remained as 18% severely 
depressed. Therefore, IA treatment was suggested for this patient which is a certified therapy 
in Germany financed by the health care insurance system after individual application.  
Blood samples including EDTA blood and serum blood were collected from the patient. This 
study was performed according to the Helsinki Declaration which was revised in 2013. Blood 
samples were collected at five different time points according to the IA treatment, which 
represent five different treatment stages (see Figure 30).  
 
Figure 30    Schematics showing treatment stages (S1‐S5) and blood sampling time points 
For the reference samples, albumin powder (bovine serum, Merck) was dissolved into sterile 
ultra-pure water (Ampuwa, KabiPac) to yield a physiological concentration of 40݉݃/݈݉, 
while stock IgG solution of 5݉݃/݈݉  (rabbit, Abcam) was used directly. The reference 
samples were also prepared as described in Section 2.2.7, but without dilution for FT-IR 
experiments. 
Immunoadsortpion (IA). This DCM patient was undertaken in one IA course. After 5 
consecutive IA treatment session days at day 5, 0.5݃/݇݃ polyclonal IgG (Venimmun N, ZLB 
Benning, Switzerland) was substituted according to the protocols published [80]. Following is 
a brief description of IA therapy: blood is separated into plasma and cellular constitutes by 
filtering; then the filtered plasma goes through protein-A IA absorber columns, which contain 
immunoadsorber for IgG (Immunosorba, Fresenius Medical Care AG, Germany). After the 
depletion of IgG, the filtered plasma is reinfused back to the DCM patient. IA system being 
used in this study is a double-column system, where one absorber column is perfused with 
plasma while the other is being regenerated at the same time. During IA process, 
anticoagulation is performed with intravenous infusion of anti-coagulate additives as heparin, 
and/or with citrate if needed additionally. The follow-up of the treatment was assessed by 
clinical examination based on blood sample and echocardiography.  
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Spectra of plasma, serum, albumin and IgG. Figure 31 shows vibrational spectra of 
IgG, albumin, serum and plasma prior to IA treatment. Typical vibrational fingerprints of 
proteins are shown, which compose as the major components of dried plasma and serum. A 
detailed band assignment is shown in Table 5. Albumin is the most abundant blood plasma 
protein accounting for most 55% of all blood plasma proteins, and the spectra of albumin and 
blood samples are expected to share similar Raman and FT-IR patterns as shown in Figure 31. 
The second most predominating proteins are Ig; which constitute about 38% of blood plasma 
proteins while IgG is the major contributions for all Ig with a percentage of 75. IgG is rich of 
ß-sheet structure reflecting Raman bands around 1240ܿ݉ିଵ  in amide III and around 
1672ܿ݉ିଵ in amide I. [92, 121] However, the IR spectra have a broader bandwidth of ca. 
59ܿ݉ିଵ  around 1642ܿ݉ିଵ  (Figure 32), which can be a hint to a preparation-induced 
denaturation of IgG (unordered segment) [176].  
 
Figure 31    Vibrational spectra of blood samples: left panel: Raman; right panel: FT‐IR. From top to bottom: IgG 
(from  rabbit, 5mg/ml),  albumin  (bovine  serum, 40mg/ml),  serum  and  plasma  from DCM  patient  before  IA 
treatment (stage S1). Spectra are shifted along the y‐axis for clarity. 
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Table 5    Assignment of Raman [90‐92] and IR bands [93‐96, 177] based on literatures 
Raman shift 
(ܿ݉ିଵ) 
IR shift 
(ܿ݉ିଵ) 
Protein Nucleic acid Lipids Carbohydrate 
758  Tryptophan  
(symmetric ring breathing) 
   
854  Try, Pro, tyrosine  
(ring breathing) 
   
939  C-C stretching backbone 
(α-helix) 
   
1004  Phenylalanine  
(symmetric ring breathing) 
   
1032  Phe  
(C-H in plane bending) 
   
 1038 ν C-0 DNA, RNA  Deoxyribose 
/ribose 
 1078 C-O stretching P0-2 symmetric 
stretching 
/DNA, RNA 
 Glycogen  
(C-O stretching) 
/deoxyribose 
/ribose 
 1118  C-O stretching of 
RNA 
Lipids  
1124  C-N stretching  C-C stretching  
1158  Carotenoids (C=C) 
 /C-C /C-N stretching 
   
 1170   Ester C-O 
asymmetric 
stretching 
 
1209  Phe, Tyr 
(C-C6H5 stretching) 
   
1240 1220-
1330 
Amide III    
1252  Amide III  =CH 
deformation 
 
1268  Amide III    
1318  C-H deformation, collagen G CH3CH2 twist  
1334  CH3CH2 wagging CH3CH2 wagging   
 1392 CH3 deformation  Lipids  
 1398 C=O stretching of COO-    
 1400 Proline /valine    
 1416   CH3 
asymmetric 
stretching 
 
1434    CH2  
1448  CH2 bending  CH2 bending  
 1452 CH2 scissoring    
 1514 Amide II 
 (ß-sheet structures) 
 /δ N-H /ν C-N 
   
1520  Carotenoids  
(C=C vibration) 
   
 1535 CH2 bending /Amide II  CH2 bending  
1552 1554 Amide II    
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 1589 Amide II    
 1642 Amide I (unordered)    
 1655 Amide I 
 (antiparallel ß-sheet 
 /aggregated strand) 
   
1659 1662 Amide I    
1674  Amide I (ß-sheet)    
 1695 Amide I  
(antiparallel ß-sheet 
 /aggregated strand) 
   
 2872 CH3 symmetric stretching    
 2920 CH2 symmetric stretching    
 2929   Lipids  
2934  CH2 symmetric stretching    
 2958 CH3 asymmetric stretching    
 3282 H-O-H stretching    
 3296 C-H stretching 
 /O-H stretching 
   
	
	
Figure 32    Bandwidth comparison of amide I in IgG from vibrational spectra: Raman 33cmିଵ; IR 59cmିଵ. 
Mean spectra of different IA treatment stages. Figure 33 show the vibrational spectra 
of plasma and serum samples from the five different stages for Raman and FT-IR 
respectively, the corresponding spectra share very similar spectral patterns overall, and only 
minor changes are detected.  
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Figure 33    Mean spectra with standard deviation (shadows) of different stages during IA treatment: Left panel: 
Raman; right panel: FT‐IR; top panel: plasma; low panel: serum. 
Difference spectra between different IA stages. To better interpret variations in the 
chemical composition of plasma and serum samples and visualize changes in chemical 
composition from the detected vibrational spectra between different IA treatment stages, two 
sets of difference spectra are calculated. One set is based on the difference between all stages 
and stage 2 shown in Figure 34, because largest variations are expected to occur at S2. A 
similar pattern can be seen for all computed difference spectra. For Raman spectra, dominant 
variations occur around 1158ܿ݉ିଵ  (positive), 1240ܿ݉ିଵ  (negative), 1520ܿ݉ିଵ  (positive) 
and 1674ܿ݉ିଵ  (negative). For FT-IR spectra, significant changes show in 1597ܿ݉ିଵ 
(positive), 1642ܿ݉ିଵ (negative) and 1662ܿ݉ିଵ (positive).The negative bands imply higher 
spectral intensities in other stages than at S2, while positive bands mark spectral features that 
are more prominent in S2. The positive bands around 1158ܿ݉ିଵ and 1520ܿ݉ିଵ from Raman 
spectra indicate that carotenoids increase immediately after IA therapy (difference spectra S2-
S1), thereafter decrease (difference spectra S2-S3, S2-S4, S2-S5). Negative bands around 
1240ܿ݉ିଵand 1674ܿ݉ିଵ from Raman spectra and 1642cm-1 from FT-IR spectra can be due 
to variations of IgG during IA treatment. The concentration of anti-cardiac antibodies (and 
related Igs) is expected to be lowest at stage 2 due to active removal during therapy, and 
increase after stage 3 as a result of IgG restoration. 
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Figure 34    Difference spectra between S2 and other stages during IA treatment: left panel: Raman; right panel: 
FT‐IR; top panel: plasma; low panel: serum. 
The other different set of difference spectra are based on consecutive treatment stages (Figure 
35). Figure 35 clearly shows that major changes appear in the difference spectra at which S2 
is involving. In other words, the strong negative bands around 1240ܿ݉ିଵ and 1674ܿ݉ିଵ 
from Raman difference spectra give a hint of higher protein content at S1 than at S2, whereas 
the same bands are found as positive contributions in the Raman difference spectra between 
S3 and S2. These phenomena can be explained by the removal of IgG at S2 but the restoration 
of antibodies at S3 as result of the substitution of fresh, pooled IgG. Other major positive 
bands observed in Raman difference spectra between S1 and S2 around 1158ܿ݉ିଵ  and 
1520ܿ݉ିଵ  are characteristics for C-C and C=C vibration from the contributions of 
carotenoids. Although carotenoids are well-known antioxidants, its level are found to relate to 
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fruit and vegetable uptake, [178] thus no further discussion about the variation of carotenoids 
will be given here due to the limited sample size of only one patient in this study. For 
difference spectra between S4 and S3, and between S5 and S4, the visible gentle variations 
can be a hint of the stable situation and well recovery of the patient almost one year after IA 
therapy. For FT-IR difference spectra shown in Figure 35, significant peaks around 
1597ܿ݉ିଵ, 1642ܿ݉ିଵ, and 1662ܿ݉ିଵ are observed, which are mainly from proteins. The 
changes of these fingerprints can also be explained by the depletion and restoration of 
antibodies corresponding to IA treatment as discussed above. 
	
Figure 35       Computed difference  spectra between different  treatment  stages during  IA  therapy:  left panel: 
Raman; right panel: FT‐IR; top panel: plasma; bottom panel: serum. 
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Correlation of IgG content from immunoturbidimetry and vibrational spectra. As 
shown in Figure 34 and Figure 35, the most distinct stage during IA treatment is S2 where the 
concentration of IgG is lowest at this stage due to the removal of anti-cardiac antibodies. The 
variation of IgG in the blood samples from the five different IA treatment stages was 
quantified via immunoturbidimetry. The immunoturbidimetry results and the correlated IgG 
content from vibrational spectra were shown in Figure 36. Raman bands around 1674ܿ݉ିଵ 
and IR bands around 1642ܿ݉ିଵ were chosen to interpreted the intensity of IgG. Similar trend 
can be observed from Raman data (Figure 36 b, e) and FT-IR data (Figure 36 c, f) as for 
immunoturbidimetry (Figure 36 a, d). Since anti-cardiac antibodies belong to IgG 3 subclass, 
by measuring total IgG, the relative IgG content can be accessed indirectly via Raman and 
FT-IR spectroscopy without the need of immunoturbidimetry. 
	
Figure 36       Changes of  IgG content during  IA therapy as quantified by  immunoturbidimetry  (a, d) as well as 
extracted  from  the  vibrational  spectra using 1674cmିଵ (Raman: b, e) and 1642cmିଵ(FT‐IR:  c,  f). Top panel: 
plasma, bottom panel: serum. 
PCA analysis. Unsupervised PCA analysis was performed to visualized spectral differences 
and similarities responding to different IA stages and the corresponding PCA scatter plots are 
shown in Figure 37. Well separated groups representing different IA stages are observed: S2 
is obviously grouped far from other stages as result of the removal of anti-cardiac antibodies; 
S1 is the second most distinct stage; whereas S3, S4 and S5 are likely to be clustered closely 
with the IgG restoration for these three stages.  
63 
 
	
Figure 37       PCA  scatter plots  for vibrational  spectral data:  left panel: Raman;  right panel: FT‐IR;  top panel: 
plasma; bottom panel: serum. All Raman spectra for 5 stages are used, where mean spectra of each scan from 
two different batches for 5 stages are applied in FT‐IR case. 
The corresponding loadings for PCA analysis are shown in Figure 38. Separation of different 
stages from Raman spectral variance is 22.6% for the first principal component on plasma 
sample and about 19.9% for serum. PC1 from Raman data mainly contains contributions from 
proteins including 1240ܿ݉ିଵ  and 1674ܿ݉ିଵ  from IgG as discussed above. The 
corresponding positive peaks in PC1 are hint for higher IgG contents. Carotenoids also play a 
role with the bands around 1158ܿ݉ିଵ  and 1520ܿ݉ିଵ  in the loadings. For FT-IR data, 
unordered segment of IgG around 1642ܿ݉ିଵ is observed for both plasma and serum which 
differentiate different stages. The main contributions to differentiate the five different stages 
come from amide II and amide I.  
PCA-SVM statistical model. PCA-SVM statistical model was built to differentiate the 
different five stages. The results for this model are shown in Table 6. For Raman dataset, 
mean classification accuracy of 96.00% and 89.00% were achieved for plasma and serum 
samples respectively. Whereas in the case of FT-IR, prediction accuracy of 80.70% and 
83.98% were approached for plasma and serum respectively. 
Table 6 shows that S3, S4 and S5 are very similar, where most misclassification is observed. 
If consider these three stages into one stages as after IA, higher accuracies of 99.01% and 
97.66% could be achieved for plasma and serum respectively (Table 7). 
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Figure 38    PCA loadings for vibrational spectral data: left panel: Raman; right panel: FT‐IR; top panel: plasma; 
bottom panel: serum. 
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Summary and discussion. The results above show that by combining vibrational 
spectroscopy with chemometric methods, the treatment stages during IA therapy of DCM 
disorder can be differentiated based on blood plasma and serum samples. The Raman and FT-
IR spectra of both plasma and serum are dominated by the contributions from proteins. 
Characteristic changes can be revealed via different spectra between different IA stages. In 
particular, S2 is distinct from other stages where all or most anti-cardiac antibodies are 
depleted. Excellent agreement for the relative changes of IgG content is found when 
extracting the spectral data and immunoturbidimetry measurement. One very important 
advantage of vibrational spectroscopy compared to conventional IgG quantification can be 
that vibrational spectroscopy allows deriving whole chemical information from the studied 
samples. This case study shows the promising possibility to follow variations in blood 
samples during IA treatment. Further studies can be elucidated to investigate the potential of 
non-invasive, label-free manner for the differentiation of responders and non-responders of IA 
therapy.  
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3.2.3 Vibrational	spectroscopic	investigation	of	patients	undergoing	
coronary	artery	bypass	grafting		
Patient cohort. Blood samples were collected before surgery (BS) and after surgery (AS) 
from 15 patients undergoing CABG (Ethic number: 4004-02/14). Four patients underwent 
surgery without the use of heart-lung machine (HLM), and the remaining 11 patients had 
surgery applying HLM. The clinical characterizations of all patients are shown in Table 8. 
53% of female were recruited. The average age for these 15 patients was 70.5(± 7.25). Blood 
hemogram including RBC, WBC (neutrophils, lymphocytes, monocytes and eosinophils), 
neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), and platelet to 
lymphocyte ratio (PLR) were recorded. Besides, plasma biomarkers such as interleukin 6 (IL 
6), procalcitonin (PCT), C-reactive protein (CRP) and cortisol were also included. Moreover, 
SOFA scores were documented.  
Table 8    Clinical characterization of CABG patients 
 
 
Vibrational spectra of leukocytes and plasma based on all patients. Leukocytes and 
plasma from the blood samples were measured with WITec alpha320 Raman system. Plasma 
was measured via FT-IR spectroscopy as well. Raman spectra of leukocytes, Raman spectra 
of plasma, FT-IR spectra of plasma from CABG patients BS and AS, and the corresponding 
difference spectra between AS and BS are shown in Figure 39. The mean vibrational spectra 
of individual samples of BS and AS are very similar (see top panels in Figure 39), thus 
corresponding difference spectra between AS and BS were calculated and shown in the 
bottom panels in Figure 39. From the difference spectra, differences between AS and BS are 
observed. These variations are mainly contributions from proteins confirmed by amide bands. 
Raman peaks around 1005ܿ݉ିଵ , 1266ܿ݉ିଵ , 1447ܿ݉ିଵ , 1572ܿ݉ିଵ , 1673ܿ݉ିଵ , and IR 
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fingerprints on 1242ܿ݉ିଵ , 1342ܿ݉ିଵ , 1412ܿ݉ିଵ , 1516ܿ݉ିଵ , 1602ܿ݉ିଵ  and 1687ܿ݉ିଵ 
are clearly observed.  
 
Figure 39    Vibrational spectra of leukocytes and plasma, a) Raman spectra of the leukocytes, b) Raman spectra 
of plasma,  c) FT‐IR  spectra of plasma. Mean  spectra are plotted with  standard deviation. Difference  spectra 
between AS and BS are presented at bottom panels. 
Vibrational spectra of leukocytes and plasma based-on gender. The chosen of on-
pump or off-pump CABG in our study depends on the patient’s condition. We did not observe 
any changes for on-pump and off-pump surgery. This can be due to low patient numbers in 
our study. The following analysis for this study will be based on gender. Mean spectra of AS 
and BS, and the resulting difference spectra corresponding to different genders are shown in 
Figure 40. On average, the variations between AS and BS are stronger in female than in male 
patients based on leukocytes, confirmed by higher Raman peaks in the difference spectra 
shown in Figure 40 (a) than in Figure 40 (d). For plasma samples, both genders have similar 
plasma composition for Raman and FT-IR spectroscopy, which are mainly contributions from 
proteins, with specific vibrational peaks shown in Figure 40 (b, c, e, f).  
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Figure  40    Vibrational  spectra  of  leukocytes  and  plasma  based  on  gender‐wise:  a)  Raman  spectra  of  the 
leukocytes from female patients, b) Raman spectra of the plasma from female patients, c) FT‐IR spectra of the 
plasma from female patients, d) Raman spectra of the leukocytes from male patients, b) Raman spectra of the 
plasma from male patients, c) FT‐IR spectra of the plasma from male patients. Mean spectra are plotted with 
standard deviation. Difference spectra between AS and BS are presented at bottom panels. 
PCA analysis based on difference spectra. PCA analysis based on difference spectra 
between AS and BS for these 15 CABG patients was performed to better visualize the 
differences or similarities among them, and to dig out more information about these patients. 
PCA scatter plots from Figure 41 show that there are some distinct outliers among these 
cohorts. Outliers P07 and P10 in Figure 41(a) are both female with body mass index (BMI) of 
31.2ܿ݉/݇݃  and 34.9ܿ݉/݇݃ individually, while outliers P02 and P06 in Figure 41(d) are 
both female with BMI of 22.7ܿ݉/݇݃ and 27.5ܿ݉/݇݃ respectively. Some patients underwent 
different conditions or complications during or after the cardiac surgery: for example P12 had 
a longer intensive care unit stay and hospital stay compared to other patients, and is outlier in 
Figure 41 (b, c, f), P14 had infection and is distinct from others in Figure 41 (d).  
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Figure 41       PCA  scatter plots  for  vibrational  spectral data: a, d) Raman  spectra of  leukocytes, b, e) Raman 
spectra of plasma, c, f) FT‐IR spectra of plasma. 
The behaviors of PCA scatter plots were not identical, efforts to explain these scatter plots are 
tried with corresponding PCA loadings. PCA loadings in Figure 42 show that contributions to 
PCA analysis based on the difference spectra are mainly from proteins, in particular with 
Raman peaks around amide I (1660ܿ݉ିଵ, 1676ܿ݉ିଵ), amide II (1556ܿ݉ିଵ, 1578ܿ݉ିଵ), 
amide III (1230ܿ݉ିଵ, 1241ܿ݉ିଵ, 1250ܿ݉ିଵ), CH2 scissoring (1452ܿ݉ିଵ), CH2 bending 
( 1446ܿ݉ିଵ ), and phenylalanine ( 1002ܿ݉ିଵ ); in addition with IR peaks on amide I 
(1604ܿ݉ିଵ , 1657ܿ݉ିଵ , 1676ܿ݉ିଵ , 1689ܿ݉ିଵ), and amide II (1518ܿ݉ିଵ , 1591ܿ݉ିଵ). 
However, the proteins contributions are different in differentiating the CABG patients before 
and after cardiac surgery, confirmed by different vibrational peaks above. This can be 
assigned to the different biomolecule components in WBCs and plasma when comparing 
Figure 42 (a) and Figure 42 (b), and distinct Raman scattering and IR absorbance for the same 
plasma when considering Figure 42 (b) and Figure 42 (c).  
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Figure 42       PCA  loadings  for vibrational spectral data: a) Raman spectra of  leukocytes, b) Raman spectra of 
plasma, c) FT‐IR spectra of plasma.  
Clinical biomarkers based on WBCs and plasma. The influence of cardiac surgery based-
on leukocytes and plasma were recorded and the gender-wise performances were plotted in 
Figure 43. The impact of the surgery on WBC counts, NLR, MLR and PLR are similar for 
both genders, indicating similar changes of leukocytes in female and male patients. After the 
cardiac surgery, more WBCs inside the patient can be activated. The increase of WBC is 
consistent with the results from other studies [100, 179-181], and can be explained by the 
demargination of neutrophils resulting from glucocorticoids, delayed migration of neutrophils 
into tissue, neutrophils apoptosis rate, and response to interleukins. [181, 182] Regarding 
different WBCs responding to the surgery, neutrophils will increase after the surgery and peak 
after 24 postoperative hours, monocytes will be unchanged and increase after 24 
postoperative hours, whereas lymphocytes and platelets will decrease. [100, 104, 181] The 
trends support our results shown in Figure 43 (a, b, c, d) as our sample were collected during 
the surgery or few hours after the surgery. 
When considering plasma biomarkers, IL-6 increased significantly during and after the 
surgery as shown in Figure 43 (e). The increase of IL-6 can be due to the inflammatory 
response, exposure of myocardium to cardioplegic arrest, the exclusion of lungs from 
circulation, activation of T cells as source for IL-6 production, stimulation and growth of 
hematopoietic precursor cells and fibroblasts. [100, 183]  The gentle increase of cortisol in 
Figure 43 (f) can be due to the quick collection time after the surgery in our case whereas the 
increase peak will show up in the first postoperative day or from 4-12 hours after surgery. 
[184, 185] PCT is a useful marker for infection or severe sepsis or organ failure, and quite 
stable in patients without the occurrence of aforementioned complications. [186, 187] In our 
patient cohort, only three patients underwent infection or sepsis, thus it is not surprising that 
the mean PCT values did not change. CRP was reported to increase in the early days after 
surgery [100] and more probably triggered by surgical trauma instead of HLM [186], since 
our sample were collected in a short time during or after the surgery, the CRP may not 
response yet.  
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Figure 43    Impact of coronary artery bypass graft surgery on leukocytes (a, b, c, d) and on plasma (e, f, g, h) 
biomarker. P‐value was calculated based on Mann‐Whitney test. * ‐‐ p‐value < 0.05, ** ‐‐ p‐value < 0.01, ns  ‐‐ 
no significance. 
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Pearson’s correlation between clinical biomarkers and vibrational spectra. Pearson’s 
correlation was performed to better understand the correlations between vibrational spectral 
data and leukocytes or plasma biomarkers. Figure 44 shows the correlation between Raman 
bands and neutrophils. The Raman peak around 412ܿ݉ିଵ correlates strongly with gender, 
hint for the Raman fingerprints of different hormone substances. Peaks around 1166ܿ݉ିଵ, 
630ܿ݉ିଵ , 1304ܿ݉ିଵ  (1698ܿ݉ିଵ ), 1684ܿ݉ିଵ  and 888ܿ݉ିଵ  have a significant negative 
correlation with BMI, PCT, RBC, Hb and HCT respectively. While Raman fingerprint at 
1604ܿ݉ିଵ  is significantly positively correlated with monocytes. The negative correlation 
means that when the intensity of the chosen vibrational band is increased, there will be a 
decrease of the corresponding parameter or biomarker. For those positive correlations, the 
increases of vibrational peaks accompany with higher biomarkers values.  
 
Figure 44    Pearson’s correlation analysis for major subtype of leukocytes: neutrophils. 
Total correlations between biomarker from blood samples (leukocytes and plasma) and 
vibrational spectra (Raman and FT-IR spectra) are calculated and shown in Table 9. Gender 
also correlated with 976ܿ݉ିଵ  based on WBCs. Body mass index (BMI) is positively 
correlated with 1421ܿ݉ିଵ and 922ܿ݉ିଵ of the Raman bands from plasma sample. IL-6 has 
negative correlation with Raman peaks around 1062ܿ݉ିଵ  and 922ܿ݉ିଵ  from WBCs and 
plasma respectively. Whereas cortisol is positively correlated with Raman peaks and FT-IR 
bands based on plasma sample. 
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Table 9    Pearson’s correlation analysis for leukocytes and plasma 
 
Summary and discussion. Our results show that CABG with and without the use of HLM 
share similar influence on the spectra of WBCs and plasma from the patients. It can be due to 
the improvements of on-pump CABG including warm surgery techniques, the improved 
biological compatibility of HLM, anti-fibrinolytic and anti-inflammatory drugs. [100] The 
PCA analysis based on difference spectra groups the patients into different clusters according 
to different patterns, showing high potential of vibrational spectroscopy for patient 
stratification. Vibrational spectra of leukocytes and plasma correlates well with clinical 
biomarkers, however larger patient cohorts will be needed to obtain further information.  
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3.3 Application	of	Raman	spectroscopy	to	diabetes	mellitus:	
HbA1c	characterization	and	diagnostics		
This section will focus on using Raman spectroscopy to characterize glycated haemoglobin in 
diabetes mellitus. 
Sample cohort. After consent informed(Ethic number: 3558-08/12; 3558-09/12), EDTA 
blood was collected from 65 people (23 healthy donors and 42 diabetic patients). For healthy 
donors, 200μ݈  EDTA blood was collected via lancet method from finger. And 2.7݈݉ 
peripheral blood collected through BD vacutainer was obtained from diabetic patients. 
Summary of the clinical information for the sample cohort are shown in Table 10 and Figure 
45.  
Table 10    Summary of the clinical information for the sample cohorts 
 Healthy cohort Diabetic cohort 
Number 23 42
Gender (Female / male) 12 / 11 9 / 33
Ages (mean ± SD) 33.60 ± 8.34 67.08 ± 11.78 
HbA1c (mean ± SD) / % 5.05 ± 0.26 7.99 ±1.75 
 
Figure 45    Overview of clinical HbA1c values from the sample cohort. 
To get the reference HbA1c values from the recruited cohort, 10μ݈  EDTA blood was 
hemolysed and measured by HPLC (TOSOH G8) in clinical routine diagnostic laboratory. 
20μ݈ EDTA blood was used for recording blood hemogram in clinical chemistry laboratory. 
For Raman spectroscopy measurements, 7݈݉ EDTA blood was prepared through blood smear 
method on CaF2 slide to get single RBC layer. After blood smear, the sample slide was dried 
under sterile hood for about 30min. The remaining EDTA blood from diabetic patients was 
centrifuge, after plasma was obtained it was stored at െ80°ܥ for further use. Preparations for 
the blood sample are shown in Figure 46. 
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Figure 46    Sample preparations for EDTA blood. 
Raman spectra of RBCs. Figure 47 shows typical Raman spectra of dried RBCs with 
predominant peaks around 676ܿ݉ିଵ , 747ܿ݉ିଵ , 993ܿ݉ିଵ , 1085ܿ݉ିଵ , 1128ܿ݉ିଵ , 
1171ܿ݉ିଵ , 1222ܿ݉ିଵ , 1302ܿ݉ିଵ , 1337ܿ݉ିଵ , 1359ܿ݉ିଵ , 1394ܿ݉ିଵ , 1430ܿ݉ିଵ , 
1555ܿ݉ିଵ, 1584ܿ݉ିଵ and 1637ܿ݉ିଵ. The peak assignments are given in Table 11. Most of 
the fingerprints can be assigned to porphyrin, correlating to the structures of hemoglobin A 
(HbA). Dried RBCs have more than 96% hemoglobin (Hb), and HbA is the most abundant 
(>90%) hemoglobin component within Hb family. Hb is metalloprotein in the RBCs, 
containing four globin protein subunits. These subunit chains are consisted of a protein chain 
associated with a heme group. The protein chain consists of two types: α- and non-α-chain, 
they have similar length but are different in amino acid sequence. The α-chain is the same in 
all human hemoglobins, while the non-α-chain can be β-chain of normal adult hemoglobin, γ-
chain of fetal hemoglobin and δ-chain of HbA2. Each protein chain is globin fold arranged 
into a set of α-helix structure, which contains a pocket binding to the heme group strongly. 
The prosthetic heme group iron protoporphyrin IX is the same in all hemoglobins. Each heme 
group contains iron ion held in the middle of a heterocyclic ring - porphyrin. The iron ion is 
linked to the N-terminal of a histidine, and the porphyrin ring is wedged into its pocket by a 
phenylalanine of α- and non-α- chain. [188, 189] Hb has many variants in adults that are 
formed by different globins and heme. More information about Hb in adults is shown in Table 
12. Hence the signal contributions in Figure 47 are mostly from HbA and partly from RBC 
membrane.  
Since glucose binds irreversible to N-terminal valines residues in ß-chains of HbA, it can be 
an indicator to monitor long term blood glucose. In clinical, HbA1c is used to evaluate the 
extent of blood glucose. Our idea is to measure RBCs directly and predict the HbA1c value 
from Raman signal. In this study, we use three approaches for test our idea. Firstly, we done 
in-vitro glycation of isolated RBCs from healthy donor to understand HbA1c related changes 
in the Raman spectra of RBCs, different concentration glucose were added into the isolated 
RBCs. Secondly, we evaluated ex-vivo glycation of RBCs from healthy donors. Finally, we 
validated ex-vivo glycation of RBCs in diabetic patients.  
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Figure	47				Mean	Raman	spectra	of	RBCs	(λex	=	532nm)	from	healthy	donor.	(n=1)	
 
Table 11    Tentative Raman assignments for RBCs [190‐192] 
Raman peak / ܿ݉ିଵ Tentative assignments 
674 δ(pyr deform)sym
747 ν(pyr breathing)
993 ν(CβCI)asym
1085 δ(=CbH2)4
1128 ν(Cβ-methyl)
1171 ν(pyr half-ring)asym
1222 δ(CmH)
1302 δ(CmH)
1337 ν(pyr half-ring)asym
1359 ν(pyr half-ring)asym
1394 ν(pyr quarter-ring)
1430 ν(CαCm)asym
1584 ν(CαCm)asym
1637 ν(CαCm)asym
 
Table 12    Summary of main hemoglobins in adult [115, 193] 
Hemoglobin Structure Percentage
A α2β2 > 90%
A1c α2(β- NH-glucose)2 3%
A2 α2δ2 2.5%
F α2γ2 0.2%
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In-vitro glycation assay of haemoglobin in isolated RBCs. Mean Raman spectra of 
incubated RBCs with different concentrations (0݉ܯ, 5݉ܯ, 30݉ܯ, 50݉ܯ, 60݉ܯ, 70݉ܯ, 
90݉ܯ) of glucose are shown in Figure 48. Most of the fingerprints are assigned to porphyrin 
as the assignments given in Table 11.  
	
	
Figure 48    Mean spectra of in‐vitro incubated RBCs with glucose of different concentrations.  
The added glucose concentration and measured HbA1c values has a linear regression 
correlation [113], and this regression relationship can be confirmed in our data shown as 
Figure 49. Glucose concentration and HbA1c value has a Pearson correlation of 98.4%, and 
R2 for this regression is about 96.8%. 
 
Figure 49        Linear  regression between added‐glucose and  in‐vitro  incubated HbA1  (determined by Pearson 
correlation). 
According to the previous discussion, the added glucose has a positive correlation with the 
incubated HbA1c value. When incubating RBCs with glucose of different concentrations, the 
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HbA will be affected differently by glucose, thus HbA1c will change in the vibrations. These 
variations are confirmed by the difference spectra between the control RBCs (0݉ܯ) and 
those added glucose cases shown in Figure 50. The difference spectra show that the changes 
are mainly delivered by the same porphyrin fingerprints around 676ܿ݉ିଵ , 747ܿ݉ିଵ , 
1174ܿ݉ିଵ, 1355ܿ݉ିଵ, and 1397ܿ݉ିଵ as presented in mean Raman spectra. These bands 
change in intensity, indicating that they get affected by glucose binding. Raman vibrations 
from RBCs are mainly contributions from HbA (>90% composition). HbA is rich of 
porphyrin and ß-chains proteins, when glucose binds to ß-chain, it alters the valine molecules 
(see Figure 51), thus changes the structures and varies the vibrational bands. To verify this, 
healthy volunteers and diabetic patients are recruited, and the results will be discussed later. 
 
Figure 50       Difference  spectra of  in‐vitro  incubated RBCs between  control  (no glucose  added, HbA1c  from 
reference method 5.1%) and glucose added ones (5mM, 30mM, 50mM, 60mM, 70mM, 90mM). 
 
 
Figure 51    Formation of glycated hemoglobin (HbA1c) via the Amadori rearrangement. [111, 115, 194, 195] 
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In order to predict HbA1c values from Raman spectra, PLSR regression model was built via 
2-layer cross-validation. Once PLSR model was built, the model was applied to predict the 
HbA1c values on every collected RBC from the remaining test sample. When the 30݉ܯ 
glucose was chosen as the test sample, optimal PLSR model can be obtained with R2 of 91.2% 
(Figure 52). For this model, 9 components are chosen once the RMSEP has the first lowest 
value, in other words when the model has lowest cross validation (CV) error. 
 
Figure 52    PLSR model with leave‐one‐sample‐out CV, data from glucose of 30mM was used as test dataset, 9 
components was chosen to build this PLSR model. 
Ex-vivo glycation determination of RBCs from healthy donors. Mean spectra for the 
healthy cohort are presented in Figure 53, Raman profiles for these donors are similar as 
Figure 47 and can be mainly assigned to porphyrin. However, slight differences are visible, 
for example HE018 around 1635ܿ݉ିଵ , HE017 for the spectral range from 900ܿ݉ିଵ  to 
1630ܿ݉ିଵ. 
 
Figure 53    Mean spectra of healthy cohorts (n=23). 
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To better interpret the variations and to understand the difference present in RBCs for healthy 
donors, difference spectra between healthy donor with lowest HbA1c value (HE017, HbA1c 
=4.4%) and other healthy donors are calculated and shown in Figure 54. The variation 
patterns between these healthy donors are similar, with most predominant peaks assigning to 
porphyrin which are observed in the mean spectra. The intensity changes in these bands can 
result from the different glucose binding to the ß-chain in different individuals, thus changing 
the molecular structures. 
 
Figure 54       Difference  spectra between healthy donor with  lowest HbA1c  value  (HE017, HbA1c=4.4%)  and 
other healthy donors. 
PLSR model based on the data from 22 healthy donors was built and shown in Figure 55. 
Data from HE005 was used as test dataset, and the PLSR model was built based on Raman 
data from other 22 healthy donors. This PLSR model was applied to predict the HbA1c value 
for HE005. The PLSR model has a R2 of 76.4%, and 12 components was chosen to build this 
model. The prediction ability of PLSR model from healthy donors is weaker than the PLSR 
model from in-vitro incubation RBCs. This difference can be from the individual variation 
between the healthy cohorts, where only one healthy donor is included in the in-vitro 
incubation. Other factors can also influence HbA1c values, including genetic factors, age, 
environment, deficiency or high doses of vitamins (B12, C, E), aspirin, alcoholism, and so on. 
[196] 
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Figure 55    PLSR model with leave‐one‐sampe‐out CV for dataset from healthy donors. Data from HE005 was 
used as test dataset, 12 components was chosen to build this PLSR model. 
Ex-vivo glycation determination from RBCs of diabetic patients. Regarding patient 
cohort, their mean spectra are quite similar, albeit some differences are observed, see Figure 
56. These differences can be better visualized in difference spectra between PA030 with 
lowest HbA1c value and other patients, see Figure 57. Similar as Figure 50 and Figure 54, the 
variation between the diabetic patients are dominated by porphyrin, giving hint to the 
structure changes of porphyrin in HbA when bound by glucose of different concentrations. 
The difference spectra between diabetic patients are more heterogeneous than the difference 
spectra between healthy donors, the heterogeneity in patients can be due to co-morbidities 
which influence the RBCs. 
 
Figure 56    Mean spectra of diabetic patients (n=42). 
measured HbA1c (%) 
pre
dic
ted
 Hb
A1
c (
%)
 
84 
 
 
Figure 57       Difference spectra between diabetic patient with  lowest HbA1c value  (PA030, HbA1c=5.6%) and 
other patients. 
The Raman data from 42 diabetic donors are used to build a PLSR model. The PLSR model is 
built based on the data from 41 patients, while PA037 was chosen as test sample. Figure 58 
shows that the PLSR model has a R2 of 52.2%, and 17 components were chosen to build the 
model. The PLSR model did not have very robust prediction ability, this can be due to the fact 
that other factors instead of only HbA1c are also taking into account when building this 
model. These factors can be individual heterogeneity, presence of hemoglobin variants, 
deficiency or high doses of vitamin B12, vitamin C, vitamin  E or conditions affecting RBC 
such as hemolytic anemias, glucose-6-phosphate dehydrogenase deficiency, pregnancy, end-
stage kidney disease, alcoholism, iron, use of antiretroviral drugs, rheumatoid arthritis, 
splenectomy, hemoglobinopathies, administration of erythropoietin.[111, 116, 196-198]. 
 
Figure 58    PLSR model with leave‐one‐sample‐out CV for dataset from diabetic patients. Data from PA037 was 
used as test dataset, 17 components was chosen to build this PLSR model. 
85 
 
Summary and discussion. Mean spectra for the measured RBCs show that the Raman 
profiles are similar and can be mainly assigned to porphyrin, albeit slight differences are also 
visible. To dig out more information on the differences, difference spectra between sample 
with lowest HbA1c value and other samples are calculated. The difference spectra share 
similar profiles, delivering the porphyrin structure changes when glucose of different 
concentrations binds to β-globin in HbA. The in-vitro incubation confirms the linear 
correlation between glucose concentration and measured HbA1c values, with Pearson 
correlation of 98.4%, and R2 about 96.8%. In order to interpret HbA1c values from Raman 
spectra, PLSR regression model was built via leave-one-sample-out-cross-validation. Data 
from one sample was chosen as test dataset whereas other samples were used as training 
dataset. Optimal components will be chosen automatically when the model has lowest CV 
error, determined by first lowest RMSEP value. Once PLSR model was built, HbA1c values 
on every collected RBC from the test sample can be predicted. PLSR model have best 
performance for the in-vitro incubation experiment with R2 of 91.2%, and lowest prediction 
ability when considering diabetic patients with only 52.2% R2. 
The results above show the potential of combining Raman spectroscopy with advanced 
chemometric methods to quantify HbA1c values on single RBC level. The different 
performance on the PLSR models can be due to many factors instead of HbA1c solely. 
Individual variation has been reported in many clinical studies, which is unavoidable. 69% 
interindividual HbA1c variance is suggested from genetic factors. [199] Besides, the 
measured RBCs have a range of ages which have different exposure degrees to hyperglycemia. 
Older RBCs expose more to hyperglycemia but contribute less to HbA1c, younger RBCs have 
less exposure to hyperglycemia but have more contribution to HbA1c. Increasing RBC mean 
age will increase HbA1c. [200, 201] Deficiency of iron, vitamin B12, erythropoietin in renal 
failure, and bone marrow suppression in alcoholism and pregnancy will all decrease 
erythropoiesis, thus increase HbA1c by increasing mean age of RBCs. [202-207] RBC 
lifespan can be increased due to splenectomy. [208] In contrast, the RBC mean age will be 
decreased by increasing reticulocytes, thus decrease HbA1c. Moreover, rheumatoid arthritis, 
splenomegaly, antiretrovirals, ribavirin, and dapsone will increase hemolysis rate thus 
decrease RBC lifespan, hence will result in decreased HbA1c. [209-212] Hemoglobin variants 
will also influence HbA1c value. [196] 
Outlook. The measured RBCs have different lifespan which affect HbA1c extent, thus 
HbA1c from single RBC will be more interesting and needed to be further investigated in the 
future. Moreover, multiple diagnostic methods or multiple biomarkers are more attractive and 
robust since they can provide more compensate information for the same clinical condition. 
Actually, HbA1c has several limitations to diagnose DM as abovementioned. Another early 
stage glycated protein - glycated albumin (GA), now is attracting more and more attention to 
become an alternative for HbA1c, especially as a mid-term glycemic indicator. Albumin is the 
most abundant protein in blood plasma, it has a half-life of 12-21 days [198]. GA presents a 
more intermediate glycemic marker compared to HbA1c, which helps to control diabetic 
condition earlier before HbA1c variation. GA in normal health is about 1% - 10%, where the 
value can be two to five fold higher in diabetic patients [197, 213]. IR absorption 
spectroscopy and Raman spectroscopy has been shown to investigate GA of different 
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concentrations successfully. GA determination via vibrational spectroscopy on donor cohorts 
can be considered in the future.	 	
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4 Summary	and	Outlook	
In the current aging society, more and more people will suffer from age-related diseases such 
as cardiovascular diseases or diabetes mellitus. To better diagnose and treat these diseases, 
individual characterisation of the patient’s unique condition is needed. Vibrational 
spectroscopy, including Raman spectroscopy and Fourier transform infrared spectroscopy 
(FTIR), is one of the favourite techniques being developed to enable personalized medicine. 
Vibrational spectroscopic techniques have the advantages of being non-destructive, rapid, and 
label-free, can be ultimately performed in high-throughput and provide biochemical 
fingerprint information on molecular level. Among the samples measured by vibrational 
spectroscopy, blood is a very popular and important specimen for personalized medicine. 
In daily clinical routine, there can be a time delay between blood collection and blood 
processing. During this time delay, individual biomolecules in the blood can disintegrate, 
which could influence the medical diagnosis. Within the scope of this work, serum samples 
from five healthy donors were collected by centrifugation after a delay time of 30݉݅݊ , 
60݉݅݊, 120݉݅݊ and 240݉݅݊ after blood collection, respectively, and temporarily stored at 
െ80°ܥ  until Raman spectroscopic characterization. The Raman spectroscopic 
characterization of the serum was performed in the dried droplet. As expected, the Raman 
spectra were dominated by the abundant albumin and immunoglobulin G. Some smaller 
spectral differences were observed due to time delay prior processing. However, with the 
small cohort (n=5) the difference pattern was not identical for all individuals. For Raman 
spectroscopic measurements of blood samples, a time delay of up to 4 hours can probably be 
tolerated in most analysis cases.   
For the vibrational spectroscopic characterization of blood plasma and serum for biomedical 
analysis, the measurement of blood samples in dried droplets is a suitable method because 
high quality spectra can be collected quickly. However, the drying of the plasma or serum 
samples in the droplet leads to an inhomogeneous coffee ring effect: a center characterized by 
crystal patterns and a homogeneous ring. Within the scope of this work, an equal number of 
spectra from the center and ring were recorded and a statistically comparison between these 
two regions was carried out. The spectral intensity in the ring zone is significantly higher than 
in the middle. This work has shown examples in which optimal results were obtained 
exclusively with spectra only from the centre or only from the ring zone, but also examples in 
which it is advisable to characterise the entire droplet. The measurement scheme proposed in 
this thesis offers the greatest flexibility for systematic plasma and serum analyses, which can 
be transferred to different cases. 
The potential of spectroscopic analysis of blood for clinical application is demonstrated in this 
thesis for typical age-related diseases, in particular cardiovascular diseases and diabetes 
mellitus. Cardiovascular diseases are very heterogeneous and can lead to different clinical 
presentations. It is of great interest for the physicians to have a fast and simple method to 
differentiate the different clinical presentations. In this work, the blood plasma and serum of 
18 cardiac patients of the Jena University Hospital as well as of 7 (plasma) and 10 (serum) 
healthy donors were characterized by vibrational spectroscopy (Raman and FTIR). 
88 
 
Chemometric analysis of the spectra shows a clear grouping of the patients into different 
clusters, which probably contain important information on the disease pattern. A more in-
depth analysis can be performed after the clinical information is released by the cooperating 
physician. Plasma and serum samples from healthy donors can be very well distinguished 
from cardiac patients. Spectroscopic signatures of carotenoids play a decisive role, as can be 
clearly seen in the difference spectra and in the principal component analysis. Carotenoids are 
found with lower concentrations in cardiac patients, which is consistent with other clinical 
studies.  
After the cardiovascular patients were well distinguished from the healthy volunteers, two 
different treatment strategies for cardiac disease were followed by vibrational spectroscopy. 
This includes the follow-up of immunoadsorption therapy in dilated cardiomyopathy and 
spectroscopic changes of peripheral leukocytes and blood plasma during coronary artery 
bypass surgery. 
For dilated cardiomyopathy, immunoadsorption therapy has been shown to remove 
circulating antibodies and to improve cardiac function. In this study, the spectroscopic 
fingerprint of blood plasma and serum during immunoadsorption therapy was monitored over 
a period of about 1 year. With the help of chemometric methods, the respective 
immunoadsorption treatment stages can be well differentiated based on the collected spectra. 
Difference spectra between different treatment stages show characteristic changes which can 
be easily explained by the biological changes caused by the therapy. The variations in 
immunoglobulin G values during therapy show excellent agreement between 
immunoturbidimetry analysis and the spectral data. The study shows a promising potential to 
follow variations during immunoadsorption therapy based on blood samples by using 
vibrational spectroscopy. 
During coronary artery bypass grafting surgery, a coronary bypass grafting restores normal 
blood flow to the obstructed coronary artery. The operation can be performed with or without 
a heart-lung machine. Spectroscopic characterization of the peripheral leukocytes and blood 
plasma of 15 patients before and after surgery showed small changes in both leukocytes and 
plasma, but these varied from patient to patient. Significant changes of leukocyte and plasma 
biomarkers can be correlated well with vibrational spectra. 
In diabetes mellitus, the value of glycated hemoglobin (Hb1Ac) is an important diagnostic 
parameter for the average blood sugar. Currently, this value is determined by high-
performance liquid chromatography (HPLC) for the mean value of all measured erythrocytes, 
but not at the level of individual erythrocyte. This work investigated the potential of Raman 
spectroscopy in combination with chemometric methods to quantify glycated hemoglobin on 
individual erythrocytes. For in-vitro glycation experiment and healthy young volunteers 
(including diabetes patients), an excellent correlation of the spectroscopic markers with the 
Hb1Ac value was found. However, studies on individual erythrocytes of older diabetes 
mellitus patients with further comorbidities showed some limitations.  
In summary, vibrational spectroscopy in combination with chemometric methods has a high 
potential to become a diagnostic method for personalized medicine. This technique requires 
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only very small amounts of blood (7μ݈ blood for HbA1c analysis, or 1μ݈ plasma and serum 
for other studies) and minimal sample preparation, providing specific information on the 
clinical picture and course of therapy. 
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5 Zusammenfassung 
In der heutigen alternden Gesellschaft werden immer mehr Menschen an altersbedingten 
Krankheiten wie Herz-Kreislauf-Erkrankungen oder Diabetes mellitus leiden. Um diese 
Krankheiten besser diagnostizieren und behandeln zu können, ist eine individuelle 
Charakterisierung des Zustands des Patienten erforderlich. Die Schwingungsspektroskopie, 
einschließlich der Raman-Spektroskopie und Fourier-Transformations-Infrarotspektroskopie 
(FTIR), ist eine leistungsstarke Technik, die für eine personalisierte Medizin entwickelt wird. 
Schwingungsspektroskopische Techniken haben den Vorteil, dass sie zerstörungsfrei, schnell 
und markierungsfrei sind, letztlich im Hochdurchsatz durchgeführt werden können und 
biochemische Informationen auf molekularer Ebene liefern. Eine ideale Probe für die 
personalisierte Medizin ist Blut, bzw. daraus gewonnenes Serum und Plasma. 
Im klinischen Alltag kann es zu einer zeitlichen Verzögerung zwischen Blutabnahme und 
Blutverarbeitung kommen. Während dieser Zeitverzögerung können sich einzelne 
Biomoleküle im Blut zersetzen, was die medizinische Diagnose beeinflussen könnte. Im 
Rahmen dieser Arbeit wurden Serumproben von fünf gesunden Spendern nach einer 
Lagerzeit von 30݉݅݊ , 60݉݅݊ , 120݉݅݊  bzw. 240݉݅݊  nach der Blutentnahme durch 
Zentrifugation entnommen und bei െ80°ܥ bis zur spektroskopischen Charakterisierung von 
Raman zwischengelagert. Die Raman-spektroskopische Charakterisierung des Serums wurde 
im getrockneten Tropfen durchgeführt. Wie erwartet, wurden die Raman-Spektren von dem 
reichlich vorhandenen Albumin und Immunglobulinen dominiert. Einige kleinere spektrale 
Unterschiede aufgrund der Lagerzeit konnten beobachtet werden. Bei der kleinen Kohorte 
(n=5) war das Differenzmuster jedoch nicht für alle Individuen identisch. Für eine allgemeine 
Raman-spektroskopische Untersuchung der Blutproben kann wahrscheinlich eine 
Zeitverzögerung von bis zu 4 Stunden in den meisten Analysenfällen toleriert werden 
Für die schwingungsspektroskopische Charakterisierung von Blutplasma und Serum für die 
biomedizinische Analyse ist die Messung von Blutproben im getrockneten Tropfen eine 
geeignete Methode, da qualitativ hochwertige Spektren in kurzer Zeit gemessen werden 
können. Die Trocknung der Plasma- oder Serumproben im Tropfen führt jedoch zum 
Kaffeering-Effekt: ein Zentrum, das durch Kristallmuster und einen homogenen Ring 
gekennzeichnet ist. Im Rahmen dieser Arbeit wurde eine gleiche Anzahl von Spektren aus 
dem Zentrum und dem Ring aufgenommen und ein statistischer Vergleich zwischen diesen 
beiden Regionen durchgeführt. Die spektrale Intensität in der Ringzone ist deutlich höher als 
in der Mitte. In dieser Arbeit werden Beispiele gezeigt, in denen optimale Ergebnisse mit 
Spektren nur aus dem Zentrum oder nur aus der Ringzone erzielt wurden, aber auch Beispiele, 
in denen es ratsam ist, den gesamten Tropfen zu charakterisieren. Das in dieser Arbeit 
vorgeschlagene Messschema bietet die größte Flexibilität für systematische Plasma- und 
Serumanalysen, die auf verschiedene Anwendungsfälle übertragen werden können. 
Das Potenzial der spektroskopischen Analyse von Blut für die klinische Anwendung wird in 
dieser Arbeit für typische altersbedingte Erkrankungen, insbesondere Herz-Kreislauf-
Erkrankungen und Diabetes mellitus, aufgezeigt. Herz-Kreislauf-Erkrankungen sind sehr 
heterogen und können zu unterschiedlichen Krankheitsbildern führen. Für die Ärzte ist es von 
großem Interesse, eine schnelle und einfache Methode zur Unterscheidung der verschiedenen 
Krankheitsbilder zu haben. In dieser Arbeit wurden das Blutplasma und Serum von 18 
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Herzpatienten des Universitätsklinikums Jena sowie von 7 (Plasma) und 10 (Serum) gesunden 
Spendern durch Vibrationsspektroskopie (Raman und FTIR) charakterisiert. Die 
chemometrische Analyse der Spektren zeigt eine klare Gruppierung der Patienten in 
verschiedene Cluster, die wahrscheinlich wichtige Informationen über das Krankheitsbild 
enthalten. Eine vertiefte Analyse kann durchgeführt werden, nachdem die klinischen 
Informationen vom kooperierenden Arzt freigegeben wurden. Plasma- und Serumproben von 
gesunden Spendern lassen sich sehr gut von Herzpatienten unterscheiden. Spektroskopische 
Signaturen von Karotinoiden spielen eine entscheidende Rolle, wie man in den 
Differenzspektren und in der Hauptkomponentenanalyse deutlich erkennen kann. Karotinoide 
werden mit niedrigeren Konzentrationen bei Herzpatienten gefunden, was mit anderen 
klinischen Studien übereinstimmt.  
Nachdem die Herz-Kreislauf-Patienten gut von den gesunden Probanden unterschieden 
werden konnten, wurden zwei verschiedene Behandlungsstrategien 
schwingungsspektroskopisch verfolgt. Dies umfasst das Follow-up der 
Immunadsorptionstherapie bei dilatativer Kardiomyopathie sowie die Untersuchung der 
Veränderung der spektroskopischen Signatur von peripheren Leukozyten und Blutplasma 
während einer Koronararterien-Bypass-Operation.  
Bei der dilatativen Kardiomyopathie hat sich gezeigt, dass die Immunadsorptionstherapie 
zirku-lierende Antikörper entfernt und die Herzfunktion verbessert. In dieser Studie wurde der 
spektros-kopische Fingerabdruck von Blutplasma und Serum während der 
Immunadsorptionstherapie über einen Zeitraum von etwa einem Jahr beobachtet. Mit Hilfe 
chemometrischer Verfahren können die jeweiligen Immunadsorptionsbehandlungsstufen 
anhand der Spektren gut differenziert werden. Errechnete Differenzspektren zwischen 
verschiedenen Behandlungsstadien zeigen charakteristische Veränderungen, die mit den 
biologischen Veränderungen durch die Therapie gut erklärbar sind. Unter anderem zeigt sich 
eine ausgezeichnete Übereinstimmung der Variationen der Immunglobulin-G-Werte während 
der Therapie aus etablierter immunoturbidimetry-Analyse der klinischen Chemie und den 
Spektraldaten. 
Während einer Koronararterien-Bypass-Operation wird durch ein koronares Bypass-
Transplantat der normale Blutfluss zur verstopften Koronararterie wiederhergestellt. Die 
spektroskopische Charakterisierung der peripheren Leukozyten und des Blutplasmas von 15 
Patienten vor und nach der Operation zeigte kleine Veränderungen sowohl bei den 
Leukozyten als auch beim Plasma, die jedoch von Patient zu Patient variierten. Signifikante 
Veränderungen von Leukozyten- und Plasmabiomarkern lassen sich gut mit 
Schwingungsspektren korrelieren. 
Bei Diabetes mellitus ist der Wert von glykiertem Hämoglobin (Hb1Ac) ein wichtiger 
diagnostischer Parameter für den durchschnittlichen Blutzucker. Derzeit wird dieser Wert 
durch die Hochleistungsflüssigkeitschromatographie (HPLC) für den Mittelwert aller 
gemessenen Erythrozyten bestimmt, jedoch nicht auf der Ebene der einzelnen Erythrozyten. 
Diese Arbeit untersuchte das Potenzial der Raman-Spektroskopie in Kombination mit 
chemometrischen Methoden zur Quantifizierung von glykiertem Hämoglobin an einzelnen 
Erythrozyten. Für In-vitro-Glykosierungsexperimente und gesunde junge Probanden (inkl. 
Diabetiker) wurde eine ausgezeichnete Korrelation der spektroskopischen Marker mit dem 
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Hb1Ac-Wert gefunden. Studien an einzelnen roten Blutkörperchen von älteren Diabetes 
mellitus-Patienten mit weiteren Begleiterkrankungen zeigten noch Einschränkungen.  
Zusammenfassend lässt sich sagen, dass die Schwingungsspektroskopie in Kombination mit 
chemometrischen Auswertemethoden ein hohes Potenzial hat, zu einer Diagnosemethode für 
die personalisierte Medizin zu werden. Diese Technik erfordert nur sehr geringe Blutmengen 
(7μ݈ Blut für die HbA1c-Analyse, oder 1μ݈ Plasma und Serum für andere Studien) und eine 
minimale Probenvorbereitung, und kann spezifische Informationen zum Krankheitsbild und 
Therapieverlauf liefern. 
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